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ABSTRACT 
Fibromyalgia (FM) is a chronic musculoskeletal disorder characterized by widespread 
pain, fatigue, and a variety of other comorbid physiological and psychological 
characteristics, including a deficit of positive affect.  Recently, the focus of research on 
the pathophysiology of FM has considered the role of a number of genomic variants.  In 
the current manuscript, case-control analyses did not support the hypothesis that FM 
patients would differ from other chronic pain groups in catechol-O-methyltransferase 
(COMT) and mu-opioid receptor (OPRM1) genotype.  However, evidence is provided in 
support of the hypothesis that functional single nucleotide polymorphisms on the COMT 
and OPRM1 genes would be associated with risk and resilience, respectively, in a dual 
processing model of pain-related positive affective regulation in FM.  Forty-six female 
patients with a physician-confirmed diagnosis of FM completed an electronic diary that 
included once-daily assessments of positive affect and soft tissue pain.  Multilevel 
modeling yielded a significant gene X environment interaction, such that individuals with 
met/met genotype on COMT experienced a greater decline in positive affect as daily pain 
increased than did either val/met or val/val individuals.  A gene X environment 
interaction for OPRM1 also emerged, indicating that individuals with at least one asp 
allele were more resilient to elevations in daily pain than those homozygous for the asn 
allele.  In sum, the findings offer researchers ample reason to further investigate the 
contribution of the catecholamine and opioid systems, and their associated genomic 
variants, to the still poorly understood experience of FM. 
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Introduction 
 
 
Fibromyalgia (FM) is a chronic musculoskeletal disorder characterized by widespread 
pain, fatigue, and a variety of other comorbid physiological and psychological conditions 
(Thieme, Turk, & Flor, 2004; Wolfe, Smyth, Yunus et al., 1990).  Diagnosing FM is 
typically accomplished through the palpation of 18 tender points, of which 11 must be 
reported by the patient as painful to meet criteria for diagnosis.  Due to the heterogeneity 
of symptom presentation, however, physicians often do not rely solely on 
musculoskeletal examination in making a diagnosis and structuring treatment, instead 
deferring to a broad-based assessment of comorbid symptoms and conditions, including 
mood disorders, sleep disturbance, fatigue, headache, and irritable bowel disorders (Katz, 
Wolfe, & Michaud, 2006).  Recent research has identified a deficit in positive affect (PA) 
among FM patients, relative to other chronic pain groups, as another distinctive feature 
characteristic of the disorder (Zautra, Fasman, Reich et al., 2005).  In the absence of PA, 
FM patients may be more vulnerable to the effects of stress and pain on negative affect 
(NA; Zautra, Johnson, & Davis, 2005). 
FM affects approximately 6 million people in America, often causing long-lasting 
physical discomfort, reduced quality of life, and functional impairment (Bernard, Prince, 
& Edsall, 2000).  The economic impact of the disorder is substantial; the physical 
disability that can accompany FM can result in direct patient health care costs of nearly 
$5,000 annually and a significant loss of work hours, and has been thought to contribute 
to the high rate of unemployment in this population (Penrod et al., 2004).  Furthermore, 
the high rate of physician visits within the FM population creates a significant burden on 
the health care system.  With an aging population, reduced pensions for retirees, and 
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increasing difficulty in finding adequate insurance coverage, the need for effective and 
efficient diagnostic and treatment options for FM patients has never been greater.   
In the exploration of the etiopathology of FM, researchers have begun to focus on the 
role of genetics.  Interindividual differences in pain sensitivity are often reported to be 
substantially greater than intraindividual differences, and so a genetic approach provides 
an opportunity to target biologically latent sources of that variation (Mogil, 1999).  
Further, evidence for a strong familial aggregation of FM has led researchers to similarly 
conclude that genetic influences may account for a significant proportion of variance in 
the population.  As such, the focus of research on FM has shifted to a variety of genomic 
variants (Buskila & Sarzi-Puttini, 2006; Limer, Nicholl, Thomson, & McBeth, 2008).  
Candidate gene association studies are popular because populations can be compared on 
the basis of the relative frequency of target alleles, and conclusions can be drawn about 
how behaviors observed between populations may relate to observed allelic differences.  
However, genetic associations with FM have been plagued by inconsistencies common to 
many candidate gene studies.  For instance, some studies have reported an association of 
the serotonin transporter gene with FM (e.g. Cohen, Buskila, Neumann, & Ebstein, 
2002), but other studies have failed to replicate those results (e.g. Gursoy, 2002).  Both 
the nonspecificity in phenotypic associations in the candidate genes and the heterogeneity 
of symptom presentation in FM may be to blame for such inconsistencies.   
The preponderance of candidate gene studies have chosen outcomes related to pain 
sensitivity, which is often an index of continuous pain self-report (i.e., the amount of pain 
one feels), pain threshold (i.e., the point at which a stimulus becomes painful), or pain 
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tolerance (i.e., the point at which a stimulus becomes intolerably painful).  However, 
none have explored affect and affective reactivity to pain within this population.  Two 
genes with functional polymorphisms have emerged as particularly attractive candidates 
for the study of the dynamic relations between pain and affect in FM: the catechol-O-
methyltransferase gene (COMT/val158met), with a variant conferring risk, and the µ-
opioid receptor gene (OPRM1/asn40asp), with a variant conferring resilience to the 
potentially harmful effects of chronic pain and NA for FM patients. 
The objective of the current study is to gain an understanding of the genetic 
influences on FM through the examination of candidate genes hypothesized to impact 
both pain and affect.  Part of the difficulty in establishing a consistent pattern of genetic 
effects on FM stems from the heterogeneity of the disorder.  Pain sensitivity is a hallmark 
of the FM diagnosis, and most candidate gene studies within the FM population have 
isolated this symptom as the phenotype of interest (Buskila & Sarzi-Puttini, 2006).  
However, disturbed affective regulation in FM is evident by the high incidence of 
depression and anxiety in this population (Thieme, Turk, & Flor, 2004), as well as a 
deficit in PA relative to other chronic pain groups (Zautra, Fasman, Reich et al., 2005).  
The current study used a daily process design to measure individual reports of pain and 
affect each for 30 days, allowing for repeated measures of pain fluctuations, which 
strengthen both the reliability and precision of pain estimation.  The exploration of 
genetic factors related to common symptoms of FM will enhance the current 
understanding of the diagnosis and treatment of the disorder.  
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Dynamic Model of Affect and FM  
Emotion is thought to exist within a dimension known as affective space 
(Cacioppo, Gardner, & Bernston, 1999).  There has been some controversy over the 
degree to which oppositely valenced affects are related within an affective space, and part 
of that controversy stems from the fundamentally distinct views of how the space is 
organized.  Russell and Carroll (1999) gave voice to the notion that affect exists on a 
bipolar continuum whereby, heuristically speaking, a unit gain in one valence should be 
met with a unit loss in its opposite valence.  One can imagine simply a straight line in 
which each pole represents the extreme high end of the range of PA and NA, 
respectively.  Under this framework, as an individual’s NA increases, his/her PA should 
decrease, thereby increasing the degree of correlation between the two affects in a 
negative direction. 
 Another conceptualization of affective space considers PA and NA as separate, 
bivariate dimensions, and specifically views stress as an integral variable in determining 
the shape of the plane that unifies the two affects (Davis, Zautra, & Smith, 2004). This 
integrative view, known as the Dynamic Model of Affect (Zautra, Smith, Affleck, & 
Tennen, 2001), holds that it is possible, if not common, to experience affective 
independence rather than affective correlation when stress is low or absent.  In contrast, 
however, when stress is high, people have greater difficulty differentiating between the 
two affects.  To visualize an affective space that allows for affective differentiation, one 
can imagine a two dimensional space with two perpendicular lines intersecting at a single 
point.  One axis represents PA and the other NA.  As an individual’s NA increases in this 
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model, his/her PA may or may not change, reflecting a degree of independence between 
the two affects.  Indeed, recent data (Ong, Bergeman, Bisconti, & Wallace, 2006) 
collected through daily process models to capture affective relations in naturalistic 
settings suggests that negative and positive affect are often independent dimensions in the 
absence of stress.  Stress, then, creates a third dimension in the affective space and serves 
to contort its shape, causing the space to shrink and affect ratings to fall to opposite poles 
of the affective distribution. 
 Although substantial evidence has been offered for both the bivariate and bipolar 
models of affect (Reich, Zautra, & Davis, 2003), the integrative perspective of the 
Dynamic Model of Affect perhaps comes closest to modeling what happens in daily life 
when emotions are influenced by both major stressors and minor hassles.  A series of 
studies from members of our research group help elucidate why stress is so influential to 
the experience and expression of emotion.  Zautra, Berkhof, and Nicolson (2002) tested 
the hypothesis that stress would narrow the affective space between PA and NA in a 
sample of healthy workers in the Netherlands.  Utilizing the experience sampling method, 
a daily process design that randomly alerted people to obtain affect and event ratings ten 
times per day for five consecutive days, Zautra and colleagues discovered that within-
person estimates of the correlation between PA and NA were higher during moments 
when a stressful event was reported than during non-stress moments.  Hierarchical linear 
modeling techniques generated within-person estimates that were obtained from repeated 
measurements and ruled out the possible confound of individual differences accounting 
for the changed relation of PA and NA during times of stress.  Additionally, a 
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contingency analysis indicated that most individuals had a higher proportion of inverse 
PA-NA correlations under stressful than nonstressful moments, rebuffing earlier 
suggestions that changes in mean levels and variance of PA and NA under stress may 
confound interpretation of the change in the degree of relation between the two affects. 
 Why would we expect stress to impact the PA-NA relation?  Stress has been 
shown to increase uncertainty, which in turn puts attentional demands on the information 
processing system (Ursin & Olff, 1993).  When one’s information processing abilities are 
taxed, affective processing becomes limited and, consequently, PA and NA become more 
inversely correlated (Linville, 1985).  During times of acute stress, this is an adaptive 
solution; the body must recruit energy to escape the most pertinent threat it faces.  Thus, 
our affective complexity diminishes in order to minimize energy expenditure, escape 
threat, and regain homeostatic balance.  Uncertainty facilitates this process by motivating 
the individual to cognitively attend to the emotion most closely tied to a stressor: NA.  
Under conditions of uncertainty, the individual must work considerably harder to 
maintain PA, and so we would expect it to diminish during these times.   
Reich, Johnson, Zautra, & Davis (2006) reported compelling evidence of the 
effect of illness uncertainty on the emotional experience in a population of FM patients.  
These patients, who have been shown to report considerably less control over their illness 
than other chronic pain groups (Smith, Christensen, Peck, & Ward, 1994), were asked to 
give ratings of PA, NA, perceived interpersonal stress, and illness uncertainty in a weekly 
diary format over a 12-week span.  Across measurements, increases in perceived stress 
predicted increases in NA and decreases in PA.  When illness uncertainty was included in 
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the model, it interacted with stress to predict PA, such that individuals high in uncertainty 
experienced a greater decrease in PA during stressful weeks than individuals low in 
uncertainty.   
 The examination of affect in the context of chronic pain provides an excellent test 
of the DMA, as the neural pathways for pain and affect share common processing 
components (Price, 2000).  Additionally, chronic pain can serve as an analog to chronic 
stress because of the severe physical and functional limitations it presents to those 
affected (Davis et al., 2004).  Following from the notion that pain and affect exhibit a 
considerable degree of neural overlap, NA is expected to be especially high during 
painful periods.  Indeed, longitudinal research has shown that, during especially stressful 
weeks, rheumatoid arthritis patients rated NA higher and PA lower when pain was 
elevated (Potter, Zautra, & Reich, 2000).  For these patients, pain is typically 
characterized by sudden and unexpected flares that can leave the patient in a state of 
functional impairment.  Similarly, pain perceived as uncontrollable in FM patients is 
associated with a shrinkage of affective space, as patients must divert resources typically 
used for complex affective processing and instead employ them for other homeostatic 
regulatory purposes.  As a result, PA should be lower and NA higher during episodes of 
elevated pain (Davis et al., 2004).   
In line with predictions offered by the Dynamic Model of Affect, Zautra, Smith, 
Affleck, and Tennen (2001) found that, during painful weeks, reduced levels of PA 
predicted heightened levels of NA in rheumatoid arthritis patients.  Importantly, these 
findings proved to be robust to alternate methodology in a replication involving FM 
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patients and daily, instead of weekly, ratings of PA, NA, and pain (Zautra et al., 2001).  
Recent findings, currently under review, suggest that elevations in pain were related to 
increases in NA and decreases in PA to a greater extent in FM patients than in a control 
chronic pain group of osteoarthritis (OA) patients (Finan, Zautra, & Davis, In Press).   
There is a great need for research on affective regulation among FM patients for 
several reasons.  Their pain is chronic and widespread, and induces greater uncertainty 
than that which is experienced by other chronic pain groups with more targeted and 
predictable pain (Smith et al., 1994).  As a result of greater uncertainty, one can expect 
more stress and greater bipolarity between PA and NA during times of stress.  Indeed, the 
literature shows that stress significantly contributes to the etiopathology of FM.  Over 
50% of FM patients also meet criteria for post-traumatic stress disorder, compared with 
6% of the general population (Sherman, Turk, & Okifuji, 2000; Staud, 2004).  
Furthermore, the chronicity of pain in FM may sufficiently tax the body so that the 
hypothalamo-pituitary-adrenal axis response to even minor elevations in stress and pain 
becomes hypersensitized (Blackburn-Munro & Blackburn-Munro, 2001; Okifuji & Turk, 
2002).  Finally, the high comorbidity of depression and anxiety in FM suggests a 
common source of affective disturbance in this group.   
Zautra, Fasman, Reich et al. (2005) explored stress, pain, and affect reports 
recorded weekly over a period of 12 weeks by FM and OA patients.  Across 
measurements, FM patients reported less PA, but similar levels of NA, compared with 
OA patients.  Stressful weeks were associated with even lower PA reports among FM 
patients, indicating a deficit in PA regulation for this group.  Thus, FM patients are 
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operating at an affective disadvantage when they encounter periods of elevated stress and 
pain.  Not only do they experience a deficit in PA at baseline, their PA diminishes more 
than would be expected when stress and pain arise.  Importantly, this effect was 
replicated with a different sample of FM and OA patients using daily, instead of weekly, 
diary methodology (Finan et al., In Press).   
Although pain is typically associated with a decline in PA, some evidence 
suggests that those FM patients capable of maintaining PA during pain episodes may be 
protected from the wide-ranging harm pain incurs on well-being (Zautra, Johnson, and 
Davis 2005).  In the Zautra et al. (2005) study, FM and OA patients were again assessed 
in a weekly diary format for 12 weeks.  For all patients, higher average levels of PA were 
associated with lower levels of NA when either pain or interpersonal stress was elevated.  
Additionally, during weeks when pain was elevated, higher PA buffered against 
elevations in NA.  The data suggest, then, that FM patients are capable of deriving 
benefits from PA.  As an extension, it may be interpreted that the difficulties in affective 
regulation that are evident in FM result, at least partly, from a deficit in PA and a failure 
to sustain available PA throughout periods of elevated pain, stress, and NA (Zautra et al., 
2005). 
Despite the recent identification of a PA deficit in FM, and several replications of 
those findings, there is currently a gap in the knowledge of what mechanisms may 
predispose FM patients to experience affective dysregulation, and how that disturbance 
may perpetuate and prolong the experience of chronic pain.  Affective responses to stress 
and pain characterized by low PA and high NA are salient phenotypes that describe a 
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common affective profile found in FM.  As such, their development over time may be 
determined by specific and identifiable genetic factors.  Two commonly studied genes, 
COMT and OPRM1, have emerged as sound candidates for the study of pain, and have 
additionally been implicated in emotional processing independent of pain states.  Several 
studies reviewed below indicate that a common variant in COMT is overrepresented in 
FM and may contribute to dysfunctional responding to affective and painful stimuli.  
Additionally, there is some indication that a polymorphism of OPRM1 may contribute to 
a lessening of pain and an enhancement of PA in FM.  Building off Zautra et al’s (2005) 
finding that PA may be a resilient resource for FM patients, it is important to seek out 
genetic factors that may influence that resource.  To help understand the role of these 
genes in affective regulation for FM patients, their neurobiological functions will now be 
explained. 
Catecholamines and the COMT Gene  
 Catecholaminergic Neurotransmission.  A substantial body of literature suggests 
a role for epinephrine, norepinephrine, and dopamine in the pathophysiology of FM.  All 
three catecholamines are intricately involved in the neural processing of affective, 
stressful, and painful stimuli.  The catecholamines take part in an exceedingly complex 
network of information processing that may, depending upon environmental conditions, 
lead to analgesia, hyperalgesia, euphoria, or negative mood.  The following section will 
briefly review the mechanisms through which the catecholamines have been proposed to 
influence the neural processing of both pain and affect.   
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Both epinephrine and norepinephrine are powerful stimulators of sympathetic 
nervous system activity, causing increased heart rate and vasodilation, among other 
metabolic effects in response to stress (Lundberg, 1999).   They arise in the adrenal 
medulla and are released as hormones recruited for the hypothalamic-pituitary-adrenal 
(HPA) axis response to stress.  In addition, both are neurotransmitters released by adrenal 
neurons that govern the behavioral drive toward fight or flight.  With regard to pain, a 
role for a dysregulated sympatho-adrenal-medullary response in nociception and, more 
specifically, FM has been described (Petzke & Clauw, 2000).    
Stress-induced analgesia is thought to occur as a result of a descending pathway 
whereby norepinephrine exerts inhibitory influence over the pronocieptive peptide known 
as substance P (Kuraishi, Hirota, Sato, 1985).  FM patients have been shown to have 
increased levels of substance P in the cerebrospinal fluid, suggesting noradrenergic 
dysfunction in these patients (Russell et al., 1994).  In an experimental test of pain 
threshold in FM patients compared with controls, Kosek & Hansson (1997) found 
evidence for a failure in descending noxious inhibitory control in response to ischemic 
pain stimulus, a process typically moderated by norepinephrine.   
In addition to its influence in facilitating stress-induced analgesia, norepinephrine 
has been implicated in hyperalgesia and the maintenance of chronic pain.  
Norepinephrine delays the release of adrenocorticotropic hormone in FM patients, and 
this may contribute to their inability to regulate stress and pain states (Wallace et al., 
2001).  Additionally, norepinephrine injection produced painful states in 80% of FM 
patients compared to 30% of rheumatoid arthritis patients and 30% of control subjects 
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(Martinez-Lavin et al., 2002).  It is unclear, however, whether norepinephrine is 
overexpressed or underexpressed in FM.  Torpy, et al. (2000) found basal plasma 
norepinephrine levels to be elevated in FM patients.  In contrast, another study found 
norepinephrine metabolites to be underrepresented in FM patients compared to healthy 
people (Russell et al., 1994).  Petzke & Clauw (2000) highlight the difficulty in the 
interpretation of data involving plasma norepinephrine levels due to variable rates of 
release and reuptake in the sympathetic nerve terminals.   
There is also evidence that epinephrine-mediated sympathetic dysregulation 
contributes to the maintenance of chronic pain states.  Injection of epinephrine produces 
hyperalgesia to nociceptive stimulation in mouse (Khasar, Miao, Gear et al., 2002) and 
human (Chen & Levine, 2005; Choi & Rowbotham, 1997) models.  The hyperalgesic 
effect of epinephrine is thought to occur through the activation of β-2 adrenergic 
receptors on primary afferent nociceptors sent from the periphery to the spinal cord 
(Khasar, Green, Miao, & Levine, 2003).  Further, peripheral epinephrine has also been 
associated with an increase in anxiety in the context of hyperalgesia to pain stimuli 
(Janssen, Arntz, & Bouts, 1998).   Among FM patients, a reduction in the epinephrine 
response to hypoglycemia is associated with greater impairment and may indicate a 
generally deficient autonomic nervous system response to stress (Adler & Geenen, 2005; 
Adler, Kinsley, Hurwitz Mossey, & Goldenberg, 1999).    
Autonomic arousal has long been thought to influence emotional arousal 
(Schachter & Singer, 1962).  During emotional arousal, norepinephrine is released in the 
locus coeruleus and projects to an abundance of brain regions, including the hippocampus 
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and amygdala (Southwick, Bremner, Rasmusson et al., 1999).  The primary role of the 
locus coeruleus in its release of norepinephrine is to attend the organism to environmental 
stimuli that require an enhanced level of vigilance.  Threatening situations that evoke fear 
result in an adaptive efflux of norepinephrine in multiple brain regions (Southwick et al., 
1999).  Repeated exposure to fear-eliciting stimuli, however, can have harmful 
consequences that are mediated by norepinephrine.  Individuals with post-traumatic stress 
disorder (PTSD) display exaggerated levels of sympathetic arousal to trauma-related cues 
(Orr, 1997).  This effect is supported by evidence that plasma norepinephrine is elevated 
among combat veterans with PTSD compared to those without (Yehuda , Siever, & 
Teicher, 1998).  Emotion-evoked norepinephrine projections to the hippocampus may 
enhance the salience of emotional memory formation, which, consequently, may serve as 
a precursor to PTSD for those exposed to trauma (Hu, Real, Takamiya et al., 2007).  As 
PTSD is a common psychiatric comorbidity with FM, it is possible that emotion-related 
norepinephrine dysregulation may contribute to the pathophysiology of the disorder. 
There is evidence indicating that epinephrine may also influence emotion through 
its effect on physiological arousal.   Mezzakappa, Katkin, & Palmer (1999) injected 
volunteers with either epinephrine or saline and then showed them short film clips 
intended to evoke fear, anger, or amusement.  Subjects were continuously monitored for 
cardiac arousal as well as electrodermal arousal and, following the viewing of the films, 
were assessed for current emotional state.  Fear-related emotion was rated as most intense 
in the epinephrine group.  This, coupled with the finding that sympathetic arousal was 
greatest in the epinephrine group during the fear-related films, may suggest that 
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epinephrine, via its effect on physiological arousal to negative cues, elicits a feeling best 
described as a negative mood state (Marshall & Zimbardo, 1979; Mezzakappa et al., 
1999).  For FM patients, who may already suffer from a PA deficit, elevated epinephrine 
levels could create a vulnerability to heightened NA, a malady from which these patients 
may have little respite. 
There is a need for research to address questions of the influence of 
norepinephrine and epinephrine in fibromyalgia, and particularly in the patient’s response 
to stress and pain.  There are data attesting to both hyperalgesic and analgesic effects of 
these catecholamines; however, studies that simply assess their relative presence or 
absence in FM patients fall short of explaining how they may contribute to the 
maintenance of chronic pain in this population.  The examination of COMT in the daily 
response to stress and pain among FM patients could provide some valuable insight into 
the role of epinephrine and norepinephrine in this patient population.   
Dopamine is another catecholamine with distinct influences on pain and affective 
processing.  The mesolimbic dopaminergic pathway is one of the primary neural 
pathways for the neurotransmitter dopamine.  Dopamine is synthesized in the substantia 
nigra and the ventral tegmentum and projects to the nucleus accumbens, as well as other 
areas in the limbic system, such as the anterior cingulate cortex and the anterior insula.  
Typically, dopamine has been implicated in the reward circuitry of substance abusers 
(Robinson & Berridge, 2003), such that dopaminergic neurons are thought to mediate the 
appraisal and interpretation of reward and uncertainty from environmental stimuli 
(Fiorillo, Tobler, & Schulz, 2003; Tobler, Fiorillo, & Schultz, 2005).  Painful stimuli 
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have also been shown to evoke a dopaminergic response in the mesolimbic dopaminergic 
pathway.  Gear, Aley, & Levine (1999) demonstrated this effect with rodents.  Exposure 
to two different forms of noxious stimuli (i.e., injection of capaicin and paw immersion) 
resulted in an analgesic response among mice being electrically stimulated, such that the 
jaw opening reflex produced by the electrical stimulation was attenuated for mice that 
had received noxious stimuli compared to mice that only received electrical stimulation.  
Further, the antinociceptive effect of the noxious stimuli was eliminated for mice injected 
in the nucleus accumbens with a dopamine antagonist.  Other research has shown that 
substance P activates dopaminergic neurons in the ventral tegmental area, producing an 
analgesic response to the formalin test in rodents (Altier & Stewart, 1999).  Additionally, 
lesions to the ventral tegmental area lead to increased sensitivity to pain, while 
stimulation to the same area produced analgesia (Sotres-Bayon, Torres-Lopez, Lopez-
Avila, del Angel, & Pellicer, 2001).  Thus, the literature provides strong support for the 
role of dopamine in the regulation of pain states. 
A tonic/phasic model of mesolimbic dopaminergic activity (Grace, 1991; Wood, 
2006) has been proposed to explain the intercellular synaptic transmission of dopamine 
during pain.  The following summarizes Wood’s (2006) model.  The phasic dopaminergic 
response occurs rapidly and transiently as a result of acute environmental stimuli, and is 
terminated through reuptake by the dopamine transporter.  Phasic dopaminergic firing, 
then, is most active in response to threats to homeostasis like pain and psychological 
stress.  Tonic dopaminergic activity is relatively constant in the extracellular space and is 
regulated by the COMT enzyme; COMT degrades tonic, free-floating dopamine, but not 
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phasic dopamine following burst firing.  Tonic dopaminergic binding typically occurs at 
the high-affinity D2 receptors expressed on dopaminergic neurons.  When tonically 
activated dopamine binds to dopaminergic neurons, phasic firing becomes inhibited.  
Thus, high tonic dopamine concentrations in the extracellular space diminish phasic 
activity.  Chronic stress can result in a reduction in phasic activity through a variety of 
pathways, including hippocampal activation, which increase tonic expression in the 
nucleus accumbens and ultimately result in hyperalgesia. 
Mesolimbic dopaminergic activity has also been shown to mediate the affective 
response to pain.  However, the findings appear counterintuitive with respect to its known 
action as a neurotransmitter of reward.  Scott, Heitzeg, Koeppe, Stohler, & Zubieta 
(2006) examined the human dopaminergic response to prolonged painful stimuli (i.e., 
continuous injection of saline solution into the jaw) through the use of positron emission 
tomography (PET).  A radioactive tracer that binds with dopaminergic D2 and D3 
receptors in the dorsal and ventral basal ganglia was imaged throughout the pain 
administration.  Mesolimbic ventral D2 and D3 receptor activity correlated with 
increased negative affect throughout the pain stimulus, as well as with the sensory and 
affective ratings of the pain itself.  Interestingly, dorsal caudate and putamen activation of 
dopamine receptors were only associated with the sensory and affective ratings of the 
pain, and not with the individual’s general affective state.  The authors concluded that 
mesolimbic dopaminergic neurotransmission extends beyond the appraisal of reward to 
include appraisal of emotionally salient stimuli of any valence.  Indeed, a similar study by 
Pruessner, Champagne, Meaney, & Dagher (2004), reported an increase in dopaminergic 
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D2 and D3 activity in the ventral striatum during a psychological stress challenge.  These 
data suggest that neural pathways for emotion may differ as a function of environmental 
demands like pain and stress.  Although dopamine has traditionally been thought to 
amplify the positive affective experience of reward, its function is clearly not limited in 
that capacity. 
Genetic Effects of COMT on Pain and Affect. The COMT gene codes for an 
enzyme that facilitates the degradation of the catecholamine neurotransmitters 
epinephrine, norepinephrine, and dopamine (Li, Warsh, & Godse, 1984).  A common 
functional single nucleotide polymorphism (SNP) of COMT (rs 4680) contains a single 
nucleotide change of guanine to adenine, which results in an amino acid substitution of 
methionine for valine at codon 158.  Individuals homozygous for the val158allele of the 
val158met polymorphism have a three to four-fold increase in enzymatic activity 
compared to those homozygous for 158met as a result of changes in thermostability of the 
enzyme (Spielman & Weinshilboum, 1981).  The heterozygous genotype (val/met) 
produces intermediate enzymatic activity, indicating that the alleles are codominant.  
Lower COMT enzymatic activity results in a higher than normal level of catecholamines, 
while higher enzymatic activity results in a relative dearth of catecholamines.  As 
reviewed above, alterations in the presence of these neurotransmitters may have profound 
effects on the systems on which they operate.  Thus, the val158met polymorphism, through 
its ability to alter the circulating levels of catecholamines, may be associated with 
functional changes in neurological systems as well as the behaviors those systems 
influence.   
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Allelic differences in the frequency of the val158met polymorphism have been 
reported in multiple samples.  Gursoy et al. (2003) were the first to report a higher 
incidence in the 158met variant in FM patients compared to controls.  In their study, the 
met/met, val/met, and val/val genotypes were represented in 19.7%, 54.1%, and 26.2% of 
patients, respectively, and 16.4%, 36.1%, and 47.5% of healthy controls, respectively.  
The 158met allele, alone, was not differentially represented in the FM patients over 
controls.  Taken together, however, the met/met and val/met genotypes were 
overrepresented in patients compared to controls.  Both Garcia-Fructoso, Lao-
Villadoniga, Beyer, & Santos (2006) and Vargas-Alarcon et al. (2007) reported similar 
differences in allelic frequencies for FM patients compared to controls in separate 
samples of Spaniards.  Interestingly, however, Vargas-Alarcon et al. found no COMT 
polymorphic differences between FM patients and controls in a population of Mexicans.  
These data support a previous finding indicating that the met/met and val/met genotypes 
conferred risk for migraine, while the val/val genotype protected against the development 
of migraine (Erdal et al., 2001).  Similarly, Hagen, Petterson, Stovner, Skorpen, & Zwert 
(2006) reported an association between the val158met polymorphism and headache.  
Migraine is highly comorbid with FM (Peres et al., 2001), and so these findings may be 
generalizable to the FM population. 
The val158met polymorphism has also been shown to contribute to increased pain 
sensitivity to experimental noxious stimuli in a sample of healthy women, although this 
effect was smaller than that observed for other highly related SNPs on COMT 
(Diatchenko et al., 2005).  Within FM, the met/met genotype is associated with greater 
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illness severity, as determined by the Fibromyalgia Impact Questionnaire, which assesses 
function, pain level, fatigue, sleep disturbance, and psychological distress (Garcia-
Fructoso et al., 2006).  Thus, the genetic influence of polymorphisms of COMT may 
reach a wide range of phenotypic characteristics of FM that depend, at least partially, on 
catecholaminergic neurotransmission. 
The affective domain is of particular interest in the clinical portfolio of FM patients, 
and, as detailed above, catecholamines play a regulatory role when affective stimuli are 
processed.  Indeed, there is some evidence to support a role for the val158met 
polymorphism in affect regulation (Smolka et al., 2005).  Healthy volunteers were 
presented with pleasant and unpleasant images during functional magnetic resonance 
imaging (fMRI).  A gene-dose effect of the 158met variant was found on blood oxygen 
level-dependent response to the affective stimuli such that increased presence of the 
158
met variant resulted in increased reactivity to aversive stimuli.  fMRI images showed 
activation in the limbic system, as well as the prefrontal cortex and the visuospatial 
attention system.  Interestingly, no genetic effects were observed for the response to 
pleasant stimuli.  These data support evidence from Zubieta et al. (2003) that the met/met 
genotype was associated with a negative affective, but not positive affective, response to 
a sustained pain stimulus. 
The 158met allele has also been associated with higher levels of anxiety (Enoch, Xu, 
Ferro, Harris, & Goldman, 2003) and depression (Ohara et al., 2006).  However, recent 
evidence that the 158met allele was associated with increased PA in a sample of healthy 
participants (Wichers, Aguilera et al., 2007) appears to contradict some of the data on the 
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COMT gene’s role in the regulation of mood.  Subjects were assessed daily through a 
diary format on the experience of positive events, as well as their appraisal of those 
events.  As the number of 158met alleles increased within the individual, so too did one’s 
ability to experience reward from positive events.  Additionally, daily PA was positive 
correlated with incidence of the 158met allele.  How can these data be resolved with prior 
evidence that the 158met allele may predispose somebody to anxiety, depression, and 
heightened negative affective arousal?  At this point, the data are not mature enough to 
adequately answer this question.  One obvious difference between the Wichers et al. 
study and those that have linked the 158met allele to negative affective processing (e.g. 
Smolka et al., 2005) is the longitudinal nature of its design.  Perhaps the 158met effect of 
enhanced tonic dopaminergic activity does not inhibit the experience of reward in the 
flow of daily life.  However, this would contradict  Smolka et al.’s (2005) laboratory 
evidence reviewed above, as well as other imaging evidence that phasic dopamine 
release, which is inhibited by tonic activity, is positively correlated with reports of 
euphoria following administration of amphetamine (Drevets et al., 2001).  The problem, 
of course, becomes even more complex when pain is a factor in the experience of 
emotion, as dopamine has been shown to promote analgesia (e.g., Altier & Stewart, 
1999), but also negative affective appraisal of painful stimuli (e.g., Zubieta et al., 2003).  
More research is clearly necessary to distinguish between the seemingly disparate threads 
of evidence for the association of COMT and affective processing. 
Some additional issues related to the mechanism of the val158met polymorphism 
remain unclear.  First, it is not known whether the val158met polymorphism, alone, can 
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account for phenotypic traits associated with the etiopathogenesis of FM.  For example, 
Diatchenko et al. (2005) mapped three separate haplotypes that, together, accounted for 
roughly 11% of the variability in pain perception, a substantial amount for a genetic 
effect.  Haplotypes are groupings of alleles from SNPs that fall within a common range of 
loci on the gene and are often in high linkage disequilibrium with each other.  The 
authors determined that the three haplotypes, each of which included an allele from the 
val158met polymorphism, differed in the amount of pain sensitivity attributable to genetic 
influence.  Both the haplotype which conferred the highest pain sensitivity and that which 
conferred the least pain sensitivity contained the G allele, which codes for the val158 
variant, while the intermediate haplotype contained the A allele, which codes for the 
met158 variant.  The implication of this finding is that the variant that has been previously 
associated with FM and pain severity does not confer the greatest vulnerability to pain 
when analyzed as part of a group of alleles from other closely related SNPs, suggesting 
that interactions of SNPs, rather than SNP variations alone, may account for between-
person effects of COMT on pain sensitivity (Diatchenko et al., 2005).  Thus, any 
exploration of the val158met polymorphism independent of other SNPs in its genomic 
region should lead to cautious interpretations of the findings until replications can be 
reported. 
Second, it is not known exactly how the changes in enzymatic activity produced by 
the val158met polymorphism translate into vulnerabilities to the development and 
maintenance of FM.  It is undisputed that the polymorphism changes the rate at which 
catecholamines are degraded, but it is less clear how those changes impact function.  As 
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noted above, norepinephrine has been shown to, under different circumstances, contribute 
to analgesia, hyperalgesia, and increased emotional arousal.  Thus, the enzymatic 
torpidity conferred by the 158met variant, through its effect on norepinephrine may also 
result in varying functional outcomes.  Additionally, increased incidence of all three 
catecholamines simultaneously may result in outcomes different from that which would 
be expected from changes in metabolic activity on any one catecholamine alone.  
Association studies can generally only provide one small piece of this ever-expanding 
puzzle, so there is still quite a long road ahead to understanding the behavioral and 
affective implications of the COMT gene.   
Despite its broad and sometimes contradictory phenotypic associations, COMT 
remains an attractive candidate gene for the study of the dynamics of pain and affect in 
FM.  Specifically, there is evidence to support a role for the 158met allele as a “risk” 
allele in the regulation of PA in the face of chronic pain.  The 158met allele has been 
consistently associated with FM and pain hypersensitivity in healthy individuals (e.g., 
Garcia-Fructoso et al., 2006; Vargas-Alarcon et al., 2005), and has also been associated 
with higher sensory and affective ratings of lab-induced pain (Zubieta et al., 2003).   
Given the evidence reviewed above, a next step is to explore the 158met allele in the 
context of affect reports as they occur throughout daily life with chronic pain.  Daily 
reports of stress, pain and affect would extend beyond the laboratory work that has 
already been done and provide a unique window into the influence of COMT within the 
FM condition.  Another necessary research step is to establish the allelic frequency of 
COMT in FM relative to other chronic pain groups.  The 158met allele is found more 
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frequently in FM patients compared to healthy controls, but it is not known if FM patients 
differ from other chronic pain groups in this regard.  Such a test would aim to answer the 
question of how specific the effects of COMT are on the FM population. 
Opioids and the OPRM1 Gene 
Opioidergic Neurotransmission. The opioid system is large and complex, 
involving a variety of peptides and receptors that become endogenously activated during 
painful episodes and can be exogenously stimulated through the administration of 
opiates.  For the purposes of the current review, I will provide a brief introduction to the 
molecular mechanisms of opioids and their receptors, and then highlight some evidence 
in support of the importance of one particular receptor class, the µ-opioid receptor 
(MOR), in the neurotransmission of pain and affect.  
Three primary peptide groups account for most of the antinociceptive activity of 
the opioid system: dynorphin, enkephalin, and β-endorphin (Przewlocki & Przewlocka, 
2001).  All three peptides act as neurotransmitters and bind to any of the three primary 
opioid receptor sites: µ, κ, and δ.  β-endorphins have a strong binding affinity at the MOR 
and exert a peripheral analgesic action in response to hyperalgesia (Przewlocki & 
Przewlocka, 2001).   Exogenous morphine also selectively binds to the MOR, in addition 
to the κ-receptor, and has the effect of inhibiting spinally ascending transmission from 
primary nociceptive afferents (Holden, Jeong, & Forrest, 2005).  The MOR facilitates 
endogenous opioid release, as well as an exogenous morphine-induced antinociceptive 
response to inflammatory pain, neuropathic pain, and chronic widespread pain, although 
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morphine’s action at the MOR tends to be least effective in combating neuropathic pain 
(Ballantyne & Mao, 2003; Holden et al., 2005; Przewlocki & Przewlocka, 2001).  
Endogenous opioid binding at the MOR may also modulate the emotional 
response to emotionally-salient environmental stimuli.  There is a high density of MOR 
receptors in the limbic areas, which include the amygdala and hippocampus among other 
temporal lobe structures (Liberzon et al., 2002). This suggests that the MOR may be 
particularly active during the situations in which the limbic system is most active: the 
processing of emotional stimuli.  Furthermore, there is evidence that amygdalar MOR 
activity regulates the anxiolytic effect of benzodiazepams (Kang, Wilson, & Wilson, 
2000).  In a PET scan study of brain activity during emotion processing, Liberzon et al. 
(2002) showed that higher baseline MOR binding potential resulted in diminished 
cerebral blood flow during the presentation of aversive emotional stimuli, suggesting that 
MOR binding buffers against the negative affective response to aversive stimuli.  
Additionally, MOR agonists have been shown to enhance pleasantness ratings in the face 
of pain, possibly via activation of the anterior cingulate cortex (Casey et al., 2000), which 
plays a crucial role in modulating both the sensory and affective dimensions of pain 
(Price, 2000).   
 Although the opioid system has been suggested to participate in the pathogenesis 
of FM, it is as yet unclear whether it is an overabundance of certain opioid peptides, a 
relative lack of peptides, a dysfunction in the binding action at the level of the receptor, 
or some combination of mechanisms that contributes to the heightened pain sensitivity 
found in FM.  Additionally, it is unclear which peptide and/or receptor should be targeted 
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in the study of opioids in FM.   For example, Dynorphin A, an opioid peptide operating at 
the κ-receptor, has been hypothesized to be involved in the pathogenesis of FM, as it has 
been known to cause allodynia in rodents when administered exogenously (Russell, 
1998).  This hypothesis has been supported by evidence that Dynorphin A is elevated in 
the cerebrospinal fluid of FM patients (Vaeroy, Nyberg, & Terenius, 1991).  Another 
group reported that elevated levels of Met-enk-Arg-Phe (MEAP), an opioid polypeptide 
with strong binding affinity at the MOR, are associated with reduced pain threshold in 
FM patients (Baraniuk, Whalen, Cunningham, & Clauw, 2004).  In contrast, β-endorphin, 
which exacts an analgesic effect at the MOR, is found to be diminished in FM patients 
compared to controls (Pannerai et al., 2002).    
 Genetic Effects of OPRM1 on Pain and Affect. The gene for MOR function, 
OPRM1, has been touted as a highly focused candidate for the study of genetic influences 
on pain (Uhl et al., 1999).  As mentioned before, β-endorphin exacts its endogenous 
analgesic effect primarily at the MOR, while morphine depends exclusively on the MOR 
for its analgesic function.  In addition, disrupted MOR function may disturb the function 
of other opioid receptors, further compromising the opioidergic response to painful 
stimuli (Sora, Funada, & Uhl, 1997).  A functional polymorphism located at position 118 
results in the substitution of guanine for adenine.  This nucleotide substitution causes a 
change in amino acid of asparagine to aspartate at position 40 on exon 1 of the mu 
receptor protein.  Functionally, the asn40asp polymorphism in OPRM1 results in a three-
fold increase in binding affinity for β-endorphin at the MOR, presenting a rationale for its 
association with pain processing (Bond, LaForge, Tian, et al., 1998; Fillingim, Kaplan, 
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Staud et al., 2005).  Unlike the val158met polymporphism, in which both alleles are 
distributed relatively evenly throughout the population, the 40asp allele is found in only 
20-30% of the population, with homozygous asp/asp genotypes representing a 
substantially smaller fraction of the distribution than heterozygous genotypes (Bond et 
al., 1998; Fillingim et al., 2005). 
 Despite the wide-ranging implications of MOR activity in pain and affective 
processing, OPRM1 has only recently been explored in these contexts.  Two studies have 
reported null findings with regard to the gene’s effect on pain sensitivity (Comptom, 
Geschwind, & Alarcon, 2003; Kim, Mittal, Iadarola, & Dionne, 2006).  One study has 
reported significant genetic variability in self-reported pain threshold.  Fillingim et al. 
(2005) administered thermal, mechanical, and ischemic pain stimuli on healthy men and 
women.  PA and NA were additionally measured using the PANAS (Watson, Clark, & 
Tellegen, 1988).  Individuals with at least one copy of the rare 40asp allele had a higher 
pressure (mechanical) pain threshold than those homozygous for asn40.  No main effects 
for genotype on pain emerged for the other painful stimuli.  However, a sex by genotype 
interaction on thermal pain threshold suggested that men with the 40asp variant may have 
higher thresholds than women that have the variant.  A trend was also reported for a sex 
by genotype interaction on PA, such that men with the rare allele tended to report less PA 
than men with the common allele.  No differences were found between genotype in 
women, or between sexes.   
Lotsch, Stuck, & Hummel (2006) found that the asn40asp polymorphism 
modulates cortical activation in response to nociceptive stimuli without influencing the 
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cortical response to nonnociceptive stimuli.  Specifically, individuals carrying the 40asp 
allele displayed cortical potentials in response to a nasal nociceptive carbon dioxide gas 
impulse that amounted to only half of the amplitude of individuals without the rare allele.  
 The data suggest that the asn40asp polymorphism on OPRM1 is a promising target 
for an association study involving a clinical pain population like FM patients.  However, 
knowledge is still extremely limited as to the value of the asn40asp polymorphism in 
predicting pain.   
There is some evidence in support of asn40asp-mediated reward processing among 
alcoholics (Oroszi & Goldman, 2004), but, to the author’s knowledge, no studies have 
linked the variant to affective components of pain.  Any attempt to explore the utility of 
the asn40asp polymorphism in the affective processing of pain, then, will remain 
exploratory.   
Although any number of opioid peptides could be justifiably examined in the 
context of FM, the functions of β-endorphin, which is upregulated at the MOR by the 
40
asp allele, are relevant to the current study for two reasons.  First, the peptide is 
important in mediating the central nervous system response to nociception, resulting in 
analgesia when binding occurs at the MOR (Bond et al., 1998).  Second, β-endorphin 
mediates hypothalamo-pituitary-adrenal (HPA) axis function in response to stress.  In 
opioid dependent people, blockade of β-endorphin by the opioid antagaonist naloxone 
results in elevated serum cortisol levels (Culpepper-Morgan & Kreek, 1997).  FM 
patients characteristically experience an erosion of positive affective resources when 
stress and pain are elevated.  Through genomic regulation of these negative and 
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homeostatically taxing states, FM patients with the 40asp allele could be expected to 
sustain PA despite the perceived threat of stress and pain.  Thus, it is possible that the 
asn
40
asp polymorphism of OPRM1 may promote resilient positive affective responding to 
elevations in pain and NA within the FM population.   
β-endorphin binding at the MOR could represent a target for pharmacotherapy, 
and knowledge of an FM patient’s MOR receptor activity could inform clinical treatment 
options.  With regard to pain, FM patients may benefit from targeted 
pharmacotherapeutics aimed at enhancing MOR affinity for the β-endorphin.  From a 
behavioral standpoint, FM patients’ stress-management skills present a clinical concern, 
as these patients often report hypersensitivity to the effects of stress on mood and pain 
levels (Okifuji & Turk, 2002).  From this perspective, enhanced β-endorphin binding at 
the MOR would be expected to benefit FM patients by helping regulate glucocorticoid 
levels in response to stress.   
Both COMT and OPRM1 satisfy criteria recently offered by Belfer and 
colleagues (2004) for optimizing the choice of candidate genes in the study of pain 
processes in humans.  First, there is strong evidence, outlined above, supporting a role for 
each candidate gene in both pain and affective processing.  Second, both genes have 
alleles with a relatively high population frequency, thereby increasing their chances of 
having an impact on behavioral phenotypes.  The 158met allele in COMT has a population 
frequency of greater than 40% (Egan et al., 2001) while the 40asp allele on OPRM1 has 
been shown to have a frequency of between 20 and 30% (Bond et al., 1998; Fillingim et 
al., 2005).  Finally, as outlined above, both proposed polymorphisms have well-
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documented functional implications at both the cellular and behavioral levels.  Taken 
together, the literature suggests that COMT and OPRM1 are attractive candidate genes 
relevant to the perception of pain and the regulation of PA in the face of chronic pain and 
stress.  It is unknown, however, whether either gene contributes to individual differences 
in the experience of naturally occurring pain and the affective regulation that occurs in its 
midst.  The current study will provide the first test of hypotheses directly related to daily 
pain and affect regulation in the FM population. 
Summary and Hypotheses 
 The current study seeks to associate two candidate genes, COMT and OPRM1, 
with the process of affective regulation during pain.  At issue is how variants on those 
genes will influence pain and affect as it is reported in the flow of daily life.  The current 
study has several advantages over previous attempts to associate genes with FM.  First, 
the control group in the current study consists of patients with OA who should experience 
pain that is relatively comparable to that of the FM patients.  The use such a control 
group extends beyond previous attempts to establish allelic frequency rates in FM, in 
which FM patients were compared to healthy controls, by establishing allelic frequency 
comparisons between two chronic pain groups.  Second, the current study will make use 
of daily diaries to obtain within-person estimates of change in pain levels from day to 
day.  By examining such an association with PA, the current study may shed light on how 
previous associations of COMT with negative affective reactivity and pain sensitivity 
may contribute to the pathogenesis of FM.   Finally, the current study will uniquely 
contribute to the literature an exploration of a possible association of OPRM1 with 
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phenotypic characteristics related to resilience within FM.  Studies to date that have 
examined genetic associations with phenotypic traits related to FM have almost 
exclusively reported on risk to elevations in pain and NA.  It is well-established that the 
OPRM1 gene influences pain sensitivity by increasing pain threshold.  The current study 
will explore whether such an association exists within the FM population and whether it 
has implications for positive affect regulation.   
 The specific aims and hypotheses are as follows: 
1. Determine if the frequencies of the 158met allele in the catechol-O-methyltransferase 
(COMT) gene and the 40asp allele in the µ-opioid receptor (MOR) gene (OPRM1) differ 
by rheumatic diagnosis.  Past research has shown the 158met allele to confer a 
vulnerability to pain sensitivity, and FM patients have been shown to carry the allele at a 
greater frequency than healthy controls.  However, to the applicant’s knowledge no 
published study has compared FM patients with another chronic pain group with regard 
to the representation of this allele. 
Hypothesis 1a. The 158met allele will have a greater frequency in FM patients and 
patients with a dual diagnosis of OA and FM compared to patients with OA only. 
Additionally, the 40asp allele in OPRM1 has been shown to be more prevalent in people 
with a low as opposed to high pain sensitivity.  FM patients have been shown to have a 
lower threshold for pain than other chronic pain sufferers.  Thus, it is expected that this 
allele will be underrepresented in the FM population relative to individuals with OA. 
Hypothesis 1b. FM and OA/FM patients will have a relative absence of the 40asp 
allele compared to OA patients. 
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2. Examine whether the val158met polymorphism influences affect reports differentially 
for FM patients with and without the “risk” 158met allele.  Past research has indicated that 
FM patients exhibit a deficit in positive affect (PA) compared to other chronic pain 
patients (Zautra et al., 2005a), and that FM patients evidence a loss of PA when pain is 
elevated relative to other groups.  However an endogenous source of this deficit has not 
been identified.  The minor 158met allele on the COMT gene has been shown to have a 
role in the processing of emotional stimuli (Zubieta et al., 2003), but its influence on 
affective processing in the FM population has not been examined.  A model for 
Hypothesis 2 is presented in Figure 1. 
Hypothesis 2. The 158met allele will exert an effect on PA, across 30 days of daily 
reporting, and a gene X environment effect will be observed, such that the 158met allele 
will have an effect on PA on days in which pain is elevated. 
3. Examine whether the asn40asp polymorphism on OPRM1 influences affect reports 
differentially for FM patients with and without the “resilient” asp allele.  Past research 
has supported a role for the the minor 40asp allele of OPRM1 in resistance to painful 
stimuli (Fillingim et al., 2005).  Further, the MOR has been implicated in the processing 
of aversive emotional stimuli (Liberzon et al., 2002).  A model for Hypothesis 3 is 
presented in Figure 2. 
Hypothesis 3. The 40asp allele will exert an effect on PA, across 30 days of daily 
reporting, and a gene X environment effect will be observed, such that the 40asp allele 
will have an effect on PA on days in which pain is elevated. 
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In the current study, the 158met allele on COMT is proposed as a “risk” allele, with 
the potential to differentiate FM patients in PA reports and positive affective reactivity to 
daily elevations in pain and NA.  To the author’s knowledge, the current study will be the 
first to establish comparable frequency rates of the 158met allele in COMT between FM 
and OA.  The inclusion of OA as a comparison group in this analysis will be crucial to 
the identification of unique risk among FM patients compared to patients with chronic 
pain of known organic origin.  Within FM, the examination of COMT as a risk factor for 
a PA deficit will add to the body of evidence established by Zautra, Davis and colleagues 
indicating that FM patients have difficulty sustaining positive affect through pain 
episodes.  The current study would be the first to explore a possible endogenous source of 
this affective disturbance in FM.  The 40asp allele in OPRM1 is proposed as a “resilience” 
allele, with the potential to identify a group of FM patients who are capable of sustaining 
PA throughout daily elevations in pain and NA.  The identification of genotypes 
associated with risk and resilience to affective regulation in FM will advance theory 
related to the etiopathology of FM.  Additionally, it will aid researchers interested in the 
development of targeted pharmacotherapeutics involving the catecholaminergic and 
opioid systems.  Finally, the current research will inform clinicians interested in more 
efficient means of diagnosing FM and establishing effective behavioral and pain 
management programs.   
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Method  
Overview 
The data that were analyzed for the current project were collected as part of a 
larger study (R01 AR46034) designed to identify factors related to adaptation to pain and 
stress in FM.  The participants from that study completed 30 days of electronic diaries 
and submitted samples containing swabbed buccal cells, from which DNA has been 
genotyped.  The current study sought to analyze the role of those polymorphisms in the 
context of daily reports of pain and affect. 
Participants 
Participants were 214 women between the ages of 38 and 72 with a physician-
confirmed diagnosis of either OA (N=86) or FM (N=46), or a dual diagnosis of OA/FM 
(N=82).  Participants were recruited in the Phoenix, AZ metropolitan area from 
physician’s offices, advertisements, senior citizen groups, and mailings to members of the 
Arthritis Foundation.  Included in the study were participants who had no diagnosed 
autoimmune disorders, a pain rating above 20 on a 0-100 scale, and/or who were not 
involved  in litigation regarding their condition.  All participants reported their diagnosis 
to research staff and subsequently signed a HIPAA release form.  Research staff then 
contacted each participant’s physician, who sent a written confirmation of the 
participant’s stated diagnosis and disconfirmed diagnosis of other autoimmune disorders.  
All participants, regardless of physician diagnosis, underwent a tender point exam 
conducted by trained research personnel supervised by licensed rheumatologists in a 
method consistent with medical standards.  A member of the research staff used a 
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dolorimeter to palpate 18 musculoskeletal regions identified by the A merican College of 
Rheumatology as tender points that can aid in FM diagnosis (Wolfe et al., 1990).  The 
results of the tender point exam were used primarily to identify outliers whose reported 
pain may have differed from expectations based on physician diagnosis.  However, the 
results of our tender point exam were not used as inclusionary criteria. 
Procedure 
After being screened into the study, participants were visited by a clinician to 
reconfirm FM diagnosis.  Next, participants were trained in our laboratory by a research 
assistant to use a laptop computer to complete daily diaries each night for 30 days.  
Participants were encouraged to call our laboratory staff immediately if a problem 
occurred with the laptop.  A built-in date-checking software program prevented data 
entry on days other than the correct day.  In the event of laptop malfunction, a research 
assistant traveled to the participant’s home to replace the malfunctioning laptop with a 
working one.  After completing the 30-day diary, participants were visited by a clinician, 
and DNA was collected from buccal cells via a cheek swab method following published 
procedures (Walker et al., 1999).  Subsequently, participants were debriefed and 
compensated for their efforts.   
Genotyping 
Genomic DNA was purified from buccal cheek swab samples by the University of 
Connecticut Health Center GCRC Core Lab.  DNA samples were placed in 96-well plates 
and genotyped using PCR based TaqMan 5’-nuclease allelic discrimination assay 
methods in the GCRC Core Lab.  Ten percent of genotypes were randomly repeated to 
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monitor reproducibility.  Additionally, the core lab repeated samples from each plate in a 
known fashion as well included water blanks and DNA samples with known genotypes to 
monitor quality control.  Assays for both markers were already in use in the GCRC Core 
Lab.  The primer and probe combinations for these assays are: COMT val158met 
polymorphism (rs4680) primers (CCCAGCGGATGGTGGAT and 
AACGGGTCAGGCATGCA), and dual labeled probes (Vic-TCCTTCAcGCCAGCGA-
MGB and Fam- TCCTTCAtGCCAGCGA-MGB); OPRM1 Asn40Asp polymorphism 
(rs1799971) primers (CCCAGCCCCGGTTCCT and TGATGGCCGTGATCATGGA), 
and probes (Vic-AGATGGCGACCTGTCC-MGB Fam-AGATGGCAACCTGTCC-
MGB). 
Measures  
Positive and Negative Affect.  PA and NA were measured in the daily diary using 
the Positive and Negative Affect Schedule (PANAS; Watson, Clark, & Tellegen, 1988).  
Participants rated 10 standard mood adjectives each for PA and NA using a 5-point scale 
from 1 (very slightly or not at all) to 5 (extremely).  Scores for the two scales were 
obtained by computing means and between-person reliabilities were computed by 
aggregating each participant’s items across all days.  Cronbach’s alpha was .95 for PA 
and .86 for NA. 
Interpersonal Stress. Both positive and negative interpersonal life events were 
assessed by administering an abridged version of the Inventory of Small Life Events 
(ISLE; Zautra, Guarnaccia, & Dohrenwend, 1986).  Events were grouped in four domains 
of the ISLE: a) friends or acquaintances, b) spouse or partner, c) family members, and d) 
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employment and co-workers.  Participants were first asked to report whether or not each 
event occurred during the day of reporting.  After responding to each domain of items, 
participants were asked, “Overall, how stressful were your relations with your (domain) 
today?”.  Responses were made on a four-point Likert scale where 1 = Not at all, 2 = A 
little, 3 = Moderately, and 4 = Extremely.  Stressfulness ratings from each of the four 
domains were then aggregated to create a single daily index of perceived stress.  This 
method has been reported elsewhere with weekly diaries (Zautra, Hoffman, Potter et al., 
1997). 
Soft Tissue Pain.  Participants were shown a body diagram with areas marked out 
in zones covering the major quadrants of the body (Affleck et al., 1996) and instructed to 
rate their soft tissue pain in 15 total areas including parts of their neck, shoulders, chest, 
upper and lower arms, upper and lower legs, back, and buttocks on a scale of zero-to-
three where zero was “No pain” and a three meant “Severe pain.”  Sum sores were 
computed from the 15 items to create an overall score of soft tissue pain.  Cronbach’s 
alpha was .93. 
Data Analysis 
The frequencies of the alleles that code for the val158met substitution in COMT 
have been reported as follows in the FM population: 12% AA (val/val), 51% AG 
(val/met), 37% GG (met/met).  To date, allelic frequency estimates are not available for 
the OA population.  However, those estimates were hypothesized to be similar to those 
observed in the general population: 22% AA (val/val), 59% AG (val/met), 19% GG 
(met/met).  Due to the functionally intermediate action of the heterozygous val/met 
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genotype, gene effects were expected to be largest for individuals with homozygous 
genotypes.  However, COMT gene effects were explored both by using the raw 
frequency of the met allele as a predictor, as well as using the trichotomous genotype as a 
predictor.  The asn40asp substitution on OPRM1 was expected in fewer than 25% of FM 
participants based on previous reports that about 25% of the general population carries 
the 40asp allele (Fillingim et al., 2005).  No known allelic frequency estimates were 
available within the FM or OA populations.  Given the rarity of the homozygous asp/asp 
genotype (2-3% in the general population; Ray & Hutchison, 2004), individuals were 
analyzed based on the presence or absence of at least one copy of the 40asp allele.   
 There were three waves of analyses for the current study.  First, the frequency of 
the “risk” 158met allele in COMT and the “resilience” 40asp allele in OPRM1 was 
compared between diagnostic groups.  Three groups were compared: FM-only patients, 
OA-only patients, and patients with a dual diagnosis of OA/FM.  It was hypothesized that 
FM patients will carry the met allele with a greater frequency than OA patients, and that 
OA patients will carry the 40asp allele with greater frequency than FM patients.  
Comparison of FM-only with OA-only diagnostic groups provides a test of the relative 
difference in the frequency of the 158met and 40asp alleles, but does not distinguish 
between a higher frequency of the 158met allele in FM, for example, from the relative 
absence of that allele in OA.  The third group provides more definitive evidence that it is 
the presence of the risk allele that is associated with FM symptom presentation, and not 
the absence of the allele that characterizes OA symptoms, provided the allele is observed 
with greater frequency in both the FM-only and OA/FM groups compared with the OA-
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only group. Diagnostic group differences in val158met genotype were explored, with 
differences expected to be greatest for the homozygous genotypes.  Chi-square tests were 
performed using SPSS 15.0 statistical software to test these hypotheses. 
 The second wave of analyses tested the association of COMT and OPRM1 
genotypes with PA reported in the daily diaries by FM patients.  Multiple regression was 
used to determine if, within the FM population, main effects of genotype on PA are 
observed.  NA and pain were averaged across days and used as covariates, and other 
factors such as age and ethnicity were probed for use as covariates.  To enhance the 
power of detecting individual differences between genotype, OA/FM patients were 
grouped with FM patients for these analyses, while OA-only individuals were excluded 
from the initial analysis.   
 The third wave of analyses tested if there was an interaction of genotype and daily 
pain on daily PA.  Specifically, these analyses tested if, on days in which pain is elevated: 
1) FM patients with the “risk” 158met allele in COMT would experience a loss of PA 
relative to patients without the “risk” allele; 2) FM patients with the “resilience” 40asp 
allele in OPRM1 would experience more PA than individuals without the “resilience” 
allele.  For COMT, it was also expected that PA would be lower with higher levels of 
158
met loading.  To test this, trichotomous genotype differences for COMT were 
examined.   
Repeated daily measurements resulted in a hierarchical nested data structure, with 
up to 30 observations nested within people.  Given such a data structure, multilevel 
modeling was the appropriate data analytic tool.  SAS PROC MIXED (Littell et al., 
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1996) was used to conduct all multilevel analyses.  Change in daily pain relative to each 
individual’s mean pain level across diary days was used as an interaction term with 
genotype.  NA was probed as a covariate in these analyses.   
Predictor variables in the current study were centered under a procedure referred 
to as group-mean centering (Nezlek, 2001) or centering within cluster (Enders & Tofighi, 
2007).  For each observation, the participant’s mean was subtracted from the daily score, 
yielding an index of within-person daily change.  Deviation scores are denoted in this 
manuscript by the Greek letter ∆.  The independent variables selected as predictors were 
modeled as deviation scores because this procedure allows for the interpretation of the 
intercept based on the individual’s mean of the independent variable of interest.  I chose 
to group-mean center all predictors because the resulting values allow for a “pure 
estimate of the Level 1 relationship between X and Y,” without the influence of variance 
at Level 2 (Enders & Tofighi, 2007, pg. 127).  In contrast, the independent variables that 
were selected as covariates in our analyses were all modeled as raw scores because they 
control for both between- and within-person differences.  As an example, if PA is the 
outcome, pain is the predictor, and NA is controlled for, our centering decisions allow for 
an interpretation of the intercept as the average value for PA when individuals are at their 
mean pain and are experiencing no NA. 
Both Level 1 (within-person) and Level 2 (between-person) variables, as well as 
cross-level interactions (Level 1 x Level 2), were modeled as predictors.  As an example, 
I will highlight the basic equations used in the present study, involving daily PA as the 
criterion:  
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Level 1: yij (Daily PA) = β0j + β1j (∆Pain) + β2j (NA) + rij    (1) 
There are i observations of PA for j individuals.  β0j yields an estimate of the average 
level of PA at the individual’s mean level of pain, when they are experiencing no NA.   
β1j  is the coefficient for the daily influence of pain on PA and β2j  is the coefficient for 
the relationship between NA and PA, serving in this model as a covariate.  rij is the 
within-person error component.  At Level 2, individual differences in the average level 
of PA are probed, along with cross-level interactions.  The Level 2 intercept is specified 
as follows: 
Level 2: β0j = γ00 + γ01 (Average Pain) + γ02 (Genotype)        (2) 
where the equation for β0j predicts each person’s Level 1 intercept from the grand 
mean, the mean level of pain, and the individual’s genotype.   The Level 2 slopes are 
specified as follows: 
Level 2: β1 = γ10 + γ 11 (Genotype)         (3) 
The second Level 2 equation models a cross-level interaction, whereby between-person 
differences in genotype (Level 2) moderate the relationship of within-person changes in 
pain (Level 1) and the outcome, daily PA.  In all models, a first-order autoregressive 
variance-covariance matrix was chosen to model the within-person variance on the 
dependent variables.   
Here we are only concerned with fixed effects, and so the Level 2 equations lack 
a random error component.  Thus, for the analyses presented in the current study, only 
the intercept was modeled as random.  The decision to model only fixed effects was 
motivated by the expectation, supported by the literature, that the gene and gene X 
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environment effect sizes would be relatively small.  In such cases, it is considered 
statistically justifiable to model only fixed effects (Nezlek, 2001). 
Weekly and daily process designs have been crucial to advancing theory 
regarding affect relations during stress and pain (Tennen & Affleck, 2002).  Early 
criticism of approaches that incorporated a bivariate model of affective processing 
suggested that unmodeled individual differences could account for some of the findings 
that indicated separate dimensions for PA and NA.  Longitudinal naturalistic studies have 
tempered some of that criticism for several reasons.  First, the calculation of within-
person slopes allows for an examination of changes in the individual over time, 
irrespective of sample peers.  Second, as will be discussed below, repeated measurements 
over time provide a significant advantage in power compared to cross-sectional designs.  
Finally, measurements of stress, pain, and affect can be obtained exceptionally close to 
when events that influence such states actually occur. 
Power 
The phenotypes proposed in the current study likely arise from complex 
mechanisms of genes, environmental stimuli, and some interaction of the two.  As a 
consequence, determining sample size is typically a crucial methodological step in 
ensuring that there will be enough statistical power to detect an effect attributable to a 
single polymorphism.  Many factors affect power in a genetic association study, and 
these have been summarized by Evans (2008).  The current study sought to examine two 
different types of genetic association.  First, differences in allelic frequency between 
diagnostic groups were probed.  Second, gene and gene X environment effects on 
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phenotypic traits were examined.    The following will address which factors are most 
likely to affect power in the proposed analyses, will present an estimate of the number or 
cases necessary to achieve 80% power with an alpha of .05 (Cohen, 1992). 
 In analyzing allelic differences between FM and OA patients, disease prevalence 
is pertinent.  Power increases as a function of disease prevalence, and so more common 
diseases come with greater power to detect an association.  FM is a relatively common 
condition, affecting 2-4% of the population, with that number increasing among women.  
The sample in the current study allows for comparisons between OA and FM patients, as 
well as between OA patients and those with OA/FM.  The OA-only controls in the 
current study were pre-screened to ensure that no control participant has been diagnosed 
with FM.  This pre-screening measure will also increase the power to detect allelic 
differences between groups.  In a case-control design such as this, power is greatest with 
equal numbers of cases and controls.  The analysis comparing OA/FM to OA patients 
satisfies this criterion, as there are nearly equal numbers of cases (N=82) and controls 
(N=86).  Evans (2008) asserts that in situations when cases and controls are not equal, 
power is greater if there are a greater number of controls than cases.  In the analysis 
comparing FM patients to OA patients, there are nearly twice as many controls (N=86) as 
cases (N=46). 
 Linkage disequilibrium (LD) refers to the degree to which a selected variant is 
related to a different allele at a different locus on the same gene.  Power to detect an 
effect is greater when LD is high.  As the measure for linkage disequilibrium, D’, 
approaches 1, one can have greater confidence that an effect can be detected from the 
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selected variant, as it may be representative of the effects of other marker alleles in its 
genomic region.  Additionally, when D’ approaches 1, it becomes more likely that the 
marker allele has a population frequency equal to the selected variant.  For COMT, the 
val158met polymorphism has been reported to be in high LD with an allelic marker in 
close proximity on the gene (D’=.96; Diatchenko et al., 2005).  For OPRM1, the asn40asp 
polymorphism has also been reported to be in high LD with an allelic marker in close 
proximity (D’=.91; Tan, Tan, Karupathivan, & Yap, 2003).  Thus, LD is a factor that 
should enhance the power to detect both val158met and asn40asp allelic differences 
between diagnoses. 
 Using Purcell, Cherny, and Sham’s (2003) genetic power calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/), power was calculated at 80% for an alpha 
level of .05 with the following parameters: population disease prevalence, population 
frequency of the high risk allele, population frequency of a marker allele, D’, control-case 
ratio, and the relative risk of the genotype.  The relative risk of the genotype is 
determined based upon the mode of inheritance—that is, whether the target allele effect is 
dominant, recessive or additive.    A dominant model assesses how many times more 
likely an individual either homozygous or heterozygous for the risk allele is to contract 
the disease than an individual homozygous for the non-risk allele.  For the asn40asp 
polymorphism, a dominant model was used since most studies have analyzed the 
presence of the 40asp compared to its absence.  Also, it is important to note that, although 
the examination of the asn40asp polymorphism will hypothesize that fewer FM patients 
will carry the allele than OA patients, the calculation of the parameters for mode of 
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inheritance will not change.  For the val158met polymorphism, an additive model was 
used because the alleles are codominant.  That is, the presence of one allele does not 
mask the effect of the other, and so heterozygous individuals are expected to express an 
intermediate phenotype.  In terms of allelic differences, it was expected that the met/met 
genotype would be most highly represented in FM patients, followed by the val/met 
genotype.  The val/val genotype, in contrast, was expected to be most highly represented 
in OA patients. 
 Calculation of the parameters reviewed above through the genetic power 
calculator (for a review of the mathematics involved, see Evans, 2008) indicated that, for 
80% power, 61 FM cases are recommended to detect a val158met allelic difference 
between FMs and OAs, while 81 OA/FM cases are recommended to detect a val158met 
allelic difference between OA/FMs and OAs.  For the asn40asp polymorphism, 115 OA 
cases are recommended to detect an allelic difference beween FMs and OAs, while 78 
OA cases are recommended to detect an allelic difference between OA/FMs and OAs.1 
 Other factors that cannot be included in a case-control calculation may, 
nonetheless, affect the power to detect the effects proposed in Hypotheses 2 and 3 in the 
current study.  Two factors should significantly enhance power.  First, the repeated-
measure design of the study will increase the stability of the measurements, as they are 
assessed over 30 consecutive days, and allow for within-person estimates of changes over 
time in the variables of interest.  As a result, power to detect a genetic effect on 
phenotypic traits other than diagnosis should substantially increase.  Second, the primary 
                                            
1
 For this latter power calculation, the number of OA cases is listed because that is the group in which the 
allele is proposed to have greater representation.  Thus, the number of cases required for power in this 
calculation should be compared to the number of actual OA cases (N=86). 
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outcome measure, PA, is a continuous measure that contains more information than a 
categorical variable and, thus, should increase the power to detect an effect (Evans, 
2008).   
Population stratification is widely considered a significant threat to internal 
validity in association studies (Cardon & Bell, 2001) and was addressed in the proposed 
analyses.  Population stratification occurs when a sample consists of individuals from 
several different subgroups in which mating over time has been non-random, potentially 
having caused intergroup differences in allelic representation.  Ethnocentric mating is the 
cardinal example of a behavior that can lead to population stratification.  Vargas-Alarcon 
et al. (2007) reported ethnic differences within the FM population in the frequency of 
158
met, and other ethnic differences have been reported elsewhere (Mannisto & Kaakkola, 
1999).  Allelic frequencies reported for the 40asp allele in OPRM1 have varied from 10-
32% in different ethnic groups (Laforge, Yuferov, & Kreek, 2000).  A preliminary 
analysis revealed that the patient sample is relatively ethnically homogenous, with 92%, 
88%, and 93% of OA, FM, and OA/FM patients, respectively, identifying as Caucasian.  
Due to the general ethnic homogeneity of the sample, Hypothesis 1, in which allelic 
differences between diagnoses were sought, may not be vulnerable to the effects of 
population stratification.  Ethnic differences were probed on the primary outcome 
variable (e.g., PA), and all analyses for Hypotheses 2 and 3 will be re-run excluding non-
Caucasian participants to test the generalizability of the results for Caucasian-only 
participants.  It is unknown if there are significant differences across ethnic groups within 
FM with respect to PA regulation.  Therefore, it was not clear whether population 
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stratification would ultimately pose a threat to Hypotheses 2 and 3 in the current study 
(Hutchison, Stallings, McGeary, & Bryan, 2004).   
 Another potential concern is whether there was power enough to detect the gene 
X environment interactions hypothesized.  Few gene X environment interactions have 
been consistently replicated (for an exception, see Caspi et al., 2003; Kendler, Kuhn, 
Vittum, Prescott, & Riley, 2005), and a variety of possibilities may account for this 
problem, including population stratification, model misspecification, inconsistency in 
measurement, and failure to properly identify a salient phenotype with endogenous 
correlates.  Additionally, it has been argued that a ‘pathology of scale,’ in which 
continuous measures are artificially dichotomized for the purposes of analysis, 
significantly increases the risk of finding spurious gene X environment interactions 
(Eaves, 2006).  To account for this potential threat to validity, the primary outcome 
measure, PA, was analyzed as a continuous measure on all gene X environment analyses. 
 
Results 
Demographics  
First, I examined demographic differences by diagnosis, the means and standard 
deviations of which are presented in Table 1.  OAs were older than both other groups 
(FM: p<.001; OA/FM: p<.05), while OA/FMs were older than FMs (p<.05).  FMs 
reported a higher average income range than the other groups (FM: $40-50,000; OA: 
$30-40,000; OA/FM: $25-30,000), but the diagnostic groups were not statistically 
different in percent reporting at or above the sample median of $30-40,000, χ2=4.23, 
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p=.12.  Diagnosis did not differentiate people in terms of education level, F(2, 
202)=1.56, p=.21, with all groups reporting “some college” on average, or ethnicity, 
with all groups mostly comprised of Caucasians, F(2, 205)=.051, p=.95.  Diagnostic 
groups did significantly differ in body mass index [BMI: weight in kilograms/((height 
in meters)2))] (FM: M=27.88, SD=5.17; OA: M=30.12, SD=8.75; OA/FM: M=31.84, 
SD=7.63), F(2, 178)=3.34, p<.05, with FM patients having a lower BMI than either OA 
or OA/FM groups.  All demographic variables were also tested as predictors of PA and 
pain among FM patients.  However, no significant associations were found.   
Diagnostic Differences in Pain and Affect 
Next, I explored diagnostic differences in pain and affect.  Means and standard 
errors of PA, NA, and pain, by diagnostic group are also listed in Table 2.  Across diary 
days, both FM and OA/FM participant groups reported more soft tissue pain on average 
than the OA group, F(2, 210)=33.66, p<.0001.  FMs and OA/FMs did not significantly 
differ in average soft tissue pain reports.  Thus, there were diagnostic differences 
indicating greater pain overall if FM was present.  Additionally, both the FM and 
OA/FM groups evidenced greater variance in soft tissue pain scores than OAs, F(2, 
211)=11.91, p<.001.  Again, the FM and OA/FM groups did not significantly differ in 
that regard.  Correlations between study variables for the full sample can be found in 
Table 3. 
Consistent with past findings regarding reports of PA among FM patients, there 
was a significant main effect for diagnosis on daily PA, F(2, 210)=10.94, p<.01, 
indicating that OA/FMs and FMs reported significantly less PA across diary days than 
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OAs (see Table 1 for means and standard errors).  FMs and OA/FMs did not 
significantly differ in PA levels.  Further, controlling for soft tissue pain did not change 
the significance or direction of the main effect of diagnosis on PA.  Diagnostic groups 
did not significantly differ in PA variance, F(2, 211)=1.46, p=.24.  Overall, the findings 
point to an affective disturbance characterized primarily by a deficit in PA for 
individuals carrying an FM diagnosis compared to those with OA-only. 
Allelic Frequency 
 For the entire sample, COMT genotypes were present in frequency rates similar to 
published findings.  The met/met genotype was present in 18.2% of the sample (N=39), 
compared with 25.7% for val/val (N=55) and 56.1% for the intermediate val/met 
genotype (N=120).  Table 4 presents allelic frequencies for each measured genotype 
within participant diagnosis.  Contrary to my hypothesis, met/met genotype frequencies 
did not significantly differ between diagnoses, χ2(4) =3.35, p=.50.  However, within both 
FM and OA/FM groups, the met/met genotype was present for 21.7% and 21.9%, 
respectively, of participants (FM: N=10; OA/FM: N=18), compared with only 12.8% of 
OA participants (N=11).  Combining the FM and OA/FM participants into a single group 
did not significantly change the results, χ2(2)=3.07, p=.21.    
As expected, the homozygous asp/asp genotype on OPRM1 was rare in the 
current sample (Entire sample: N=6; FM-only: N=1).  As a result, asp/asp and asp/asn 
genotypes were combined such that the presence of the asp allele was contrasted with the 
asn/asn homozygous genotype.  Across the entire sample, the asp allele was present in 
28.0% of participants, while the asn/asn genotype was present in 72.0%.  Significant 
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diagnostic differences were not found in OPRM1 allelic distribution, χ2(2)=.59, p=.74.  
The percentages for both OPRM1 genotypes between diagnoses can be found in Table 4.  
Among FM participants, 23.9% (N=11) carried the asp allele, compared with 28.0% of 
OA/FM participants (N=23) and 30.2% of OA participants (N=26).  As these are the first 
allelic frequencies of the asn40asp polymorphism on OPRM1 reported for a clinical 
sample of FM patients, comparisons to other similar clinical samples are impossible.  
However, it is apparent that the frequency rates found in the current study, regardless of 
diagnosis, are consistent with general population estimates (Fillingim et al., 2005). 
Gene and Gene X Environment Effects on PA 
 The next analytic step was to determine if there were any gene and/or gene X 
environment effects on PA, as reported across the span of diary days, within the FM 
sample.  All analyses modeled PA as the outcome and NA as a covariate.  For FM-only 
patients, COMT genotype was not associated with PA across diary days, F(2, 42)=.05, 
p=.95 (for means and standard deviations, see Table 5).  This result did not change 
significantly when FM-only and OA/FM patients were analyzed together, F(2, 124)=.82, 
p=.45.  However, a significant gene X environment interaction was evident for FM-only 
patients, F(2, 1217)=4.49, p<.05 (for complete multilevel statistics, see Table 6), such 
that individuals with met/met genotype experienced a greater decline in PA as daily soft 
tissue pain increased than did either val/met or val/val individuals.  The latter two 
genotypic groups were not significantly different from each other, suggesting that the 
effect observed was recessive and, thus, was present only for met/met homozygotes.  
Figure 3 graphically depicts the COMT X daily pain interaction after dichotomizing pain 
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into top and bottom thirds of responding within the sample.  Additional analyses revealed 
useful information pertaining to the chosen phenotype.  First, with regard to the outcome, 
COMT genotype was not related to NA across diary days, F(2, 42)=.52, p=.60, and did 
not interact with daily pain in the prediction of NA, F (2, 1217)=1.90, p=.15.   Second, 
with regard to the predictor, COMT did not interact with daily interpersonal stress in the 
prediction of PA, F(2, 1192)=1.01, p=.36.  Taken together, the findings suggest that the 
chosen phenotype, daily PA reactivity to pain, most closely approximated the 
endogenous influence of the val158met polymorphism on COMT in FM patients.   
 OPRM1 genotype evidenced a trend toward a significant prediction of PA across 
diary days for FM-only patients, F(1, 43)=3.62, p=.06.  FM-only patients with the 40asp 
allele (M=2.78, SD=.80) reported higher PA across diary days than those homozygous 
for asn40 (M=2.26, SD=.74).  Means and standard deviations of PA by genotype and 
diagnosis can be found in Table 5.  The hypothesis that an OPRM1 X daily pain 
interaction would be observed was supported, F(1, 1218)=6.06, p<.05 (for complete 
multilevel statistics, see Table 7).  This effect is graphically displayed in Figure 4.  As the 
graph indicates, FM-only patients with the 40asp allele experienced a greater decline in 
PA as daily soft tissue pain increased than did those carrying two asn40 alleles.  Still, as 
Figure 4 indicates, 40asp carriers reported substantially greater PA than their counterparts 
on high pain days.  NA did not significantly moderate that interaction, F(1, 1215)=.39, 
p=.53.  However, further analyses revealed a significant OPRM1 X daily pain interaction 
on NA, F(1, 1218)=5.22, p<.05, such that FM-only 40asp carriers reported a greater 
increase in NA as pain increased than those without the 40asp allele.  As with COMT, 
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OPRM1 did not interact with daily interpersonal stress to predict PA, F(1, 1193)=.10, 
p=.76. 
 Each genotype was entered as a predictor of both soft tissue pain variance and PA 
variance.  Met/met individuals evidenced significantly greater soft tissue pain variance 
than val/val individuals, F(2, 43)=3.40, p<.05, but did not differ from the heterozygous 
genotype.  FM patients did not significantly vary by COMT genotype in PA variance 
across diary days, and did not significantly vary by OPRM1 genotype in either pain or 
PA variance. 
 Two population stratification control measures were taken with all gene and gene 
X environment effects.  First, when ethnicity was included as a covariate, the form and 
significance of the effects reported for both COMT and OPRM1 remained consistent.  
Second, when all primary COMT and OPRM1 analyses were re-run with a Caucasian-
only sample, the N decreased from 43 to 35.  The result was that the significance of each 
effect reported above dropped below the a priori alpha threshold (p<.05), but the form 
and direction of all effects remained consistent.  In sum, there is little evidence to suggest 
that population stratification was a threat to the hypotheses tested in the current study. 
Influence of Tender Point Endorsement 
When assessed by trained members of our research staff, some participants 
endorsed tender point pain discordant with their physician-confirmed diagnosis.  For a 
diagnosis of FM, pain should be present in 11 of 18 tender points.  Ten FM-only and 11 
OA/FM patients reported pain in fewer than 11 out of 18 tender points, while 27 OA-
only participants reported pain in 11 or more tender points.  One FM and three OA/FM 
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participants lacked tender point exam data.  Ultimately, the physician-confirmed 
diagnosis is the gold-standard and was used to classify diagnosis for the analyses 
presented above.  However, because the present study is concerned with FM-specific 
risk and resilience to daily pain, this finding motivated several tests for the possible 
confound of individual differences in tender point endorsement.  First, correlations 
between tender point endorsement and genotype were examined.  Tender point 
endorsement was not significantly related to either COMT, r=.13, p=.07, or OPRM1, 
r=-.08, p=.26, genotype. The case-control chi square analyses of allelic frequency were 
re-run to include only those physician-diagnosed FM and OA/FM participants who 
endorsed pain in 11 or more tender points, and only those physician-diagnosed OA 
participants who endorsed pain in fewer than 11 tender points.  The results using the 
modified sample according to tender point endorsement were consistent with those 
reported above using the sample determined by physician diagnosis.  That is, diagnostic 
groups still did not significantly differ in the allelic representation of either the COMT 
or OPRM1 genes after individuals with tender point endorsements discordant with their 
physician diagnosis were removed from the analyses.  In analyses involving continuous 
phenotypic traits of FM patients, two controls were implemented.  First, all analyses 
were run separately including only those FM patients who reported pain in 11 or more 
tender points.  Results of these separate analyses did not significantly differ from 
results run with the full sample.  Second, the number of tender points endorsed was 
included as a covariate in analyses involving the full sample of FM patients.  No effects 
were significantly altered through the inclusion of raw tender point endorsement as a 
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covariate.  Thus, it is unlikely that individual differences in tender point endorsement 
affected any of the results reported in the current study.   
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Discussion 
The purpose of the present study was to test the relation of two hand-selected 
candidate genes to positive affective regulation during pain.  To meet this aim, the study 
took two approaches.  The first approach sought to determine if alleles on COMT and 
OPRM1 that were hypothesized to confer risk and resilience, respectively, to the 
maintenance of positive affect through elevations in daily pain were differentially 
represented by rheumatic diagnosis.  The motivation of this aim was driven by the fact 
that both of the chosen genes have previously been associated with pain processes and 
affective processes, and one of the genes, COMT, has been identified as 
disproportionately represented in FM patients compared to healthy controls.  My goal 
was to further specify the relation of those genes to the dual processes of widespread pain 
and positive affective regulation that distinguish FM patients from patients with more 
targeted chronic pain.  In pursuit of this aim, allelic frequencies were compared between 
three diagnoses: FM, OA, and individuals with a dual diagnosis of OA and FM.   
Contrary to the hypothesis, the met/met allele of the val158met single nucleotide 
polymorphism on the COMT gene was not significantly overrepresented in the FM group 
compared to the OA group.  However, examination of the raw percentage representation 
within each diagnosis warrants future testing of this hypothesis with a larger sample.  The 
met/met allele was similarly represented in both the FM and OA/FM groups and 
represented a nearly 60% greater proportion of COMT genotypes in those groups 
compared to OA participants.  However, several abnormalities in the current data deserve 
mentioning.  Although the 18.2% overall met/met representation in the current sample 
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was consistent with previously published estimates of healthy controls, the representation 
within the OA group, at 12.8%, was somewhat lower than expected (≈19%), and the 
representation for patients with an FM diagnosis, at roughly 22% between the two FM 
groups, was markedly lower than published estimates (≈37%).  Given the limited sample 
size in the current study, explanations for these discrepancies will require further testing 
with a larger sample.  From the current data, competing hypotheses about allelic 
differences can be generated.  Either the current estimates are disproportionately low due 
to the low sample size in the current study, or the previously published estimates are 
disproportionately high due to the low sample sizes in those studies (N=110 in Garcia-
Fructoso et al., 2005; N=29 in Vargas-Alarcon et al., 2007).  Another possible 
explanation for the discrepancies in allelic frequency observed here could be the threat of 
population stratification in previous samples.  In the Garcia-Fructoso et al. and Vargas-
Alarcon et al. studies, Spanish and Mexican populations comprised the entire samples.  
The current study, in contrast, was comprised of mostly Caucasians which, theoretically, 
should represent a more heterogeneous background.   
It was also hypothesized that allelic differences would emerge between diagnostic 
groups in the representation of the asp allele on the OPRM1 gene.  However, the results 
indicated that the asp allele was relatively evenly distributed across diagnostic groups.  
Thus, there is a lack of evidence to suggest that the asp allele is underrepresented in FM 
patients compared to other chronic pain groups.  This finding suggests that the OPRM1 
gene may not be involved in the development of FM.  That is, those who lack an asp 
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allele do not appear to be at any significant risk of developing FM relative to the rest of 
the population.   
The second major focus of the current study was to examine the relation of the 
candidate genes to the process of positive affective reactivity to daily pain, among the 
FM-only participants, through a daily diary format.  Indeed, an interesting pattern of 
results emerged.  With regard to COMT, there was no evidence for a main effect of 
genotype on positive affect, across diary days.  In the development of hypotheses for the 
current study, it was clear that COMT has been implicated in affective processing, but the 
specificity of that association was in question.   For example, Smolka et al. (2005) found 
that the 158met allele was associated with increased reactivity to aversive, but not 
pleasurable, stimuli.  Zubieta et al. (2003) found the 158met allele to be associated with the 
negative affective, but not the positive affective, component of pain on the McGill Pain 
Questionnaire.  In contrast, Wichers et al. (2007) found that the 158met allele was 
associated with a greater capacity to experience reward. The present study sought to 
determine if the 158met allele was related to PA across diary days for FM patients.  In 
essence, this served as a test of the association of the 158met allele with trait positivity in 
this patient group.  The results of the present investigation clearly indicate an absence of 
such an association, suggesting that the relation of COMT to FM as previously displayed 
through case-control studies of allelic frequency does not primarily occur via an affective 
circuit.  However, as hypothesized, COMT moderated the relation of daily pain to daily 
PA such that elevations in pain were associated with lower PA to a greater degree among 
met/met individuals than their counterparts.  A gene-dose effect was not observed, as the 
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heterozygous group closely resembled the homozygous val/val group.  Thus, allelic 
codominance was not supported for the PA reactivity phenotype in FM patients.  This 
finding suggests that the lower enzymatic activity on catecholamines conferred by the 
met/met genotype affects FM patients’ ability to maintain PA in the face of pain flares.  
Importantly, this finding stands in contrast to Zubieta et al.’s (2003) finding that COMT 
was not associated with the positive affective components of pain.  The current study 
differs in sample constituency (FM patients vs. normative population), methodology 
(daily diary vs. laboratory pain manipulation), and measurement (PANAS vs. McGill 
Pain Questionnaire), and so comparing results must be qualified by those major 
differences.  Still, the contrast offers a chance to highlight the concomitant PA deficit 
with widespread pain in FM.  It seems that the chronic pain process for FM patients is 
almost inextricably intertwined with a deficit in PA regulation, and COMT may bear 
some responsibility for that effect.  The upshot is that the association of COMT and pain 
is variable and context-dependent. 
As reviewed above, the COMT moderation of the relation of daily pain and daily 
PA could stem from the val158met SNP’s effect on adrenergic, noradrenergic, or 
dopaminergic activity, or some combination thereof.  One goal of behavioral genetics is 
to reduce the gap between the gene and distal, macro-level behaviors, the cause of which 
can be polygenic, environmental, or both.  This is accomplished through the 
identification of brain systems, and specific processes within them that can serve as more 
proximal representatives of the gene’s work—the endophenotype (Gottesman & Gould, 
2003).  The findings presented in the current study should serve as a starting point for the 
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identification of a putative endophenotype for the deficit in positive affective regulation 
for FM patients.  Of the three catecholamine systems, the dopaminergic system offers the 
most promising direction for future study in that regard.  The tonic/phasic model of 
mesolimbic dopaminergic neurotransmission, in particular, is an attractive choice because 
it is discreet and observable, directly regulated by COMT, functions in the absence of 
disease, and has been reported to affect both the perception of pain and the experience of 
reward.  A next-step could be to target the tonic/phasic firing of dopamine in subjects, 
perhaps non-human, who are homozygous for the val158 allele (i.e., high enzymatic 
activity) and determine if disruption of the phasic response to pain results in similar 
affective deficits.   
In contrast to COMT, both gene and gene X environment effects on daily PA 
were found for OPRM1.  FM patients with at least one 40asp allele reported significantly 
more PA across diary days than those homozygous for asn40.  On days when pain was 
elevated, however, 40asp individuals report a greater decrease in PA than those 
homozygous for asn40.  This interaction could have multiple interpretations.  One 
possibility could be that 40asp individuals experience more PA, in general, than their 
counterparts, but face greater instability their positive affective reactivity to pain.  An 
alternate interpretation could be that asn40 individuals are displaying a floor effect and, if 
not for their maximally low PA, we would only be seeing an OPRM1 main effect on PA.  
The likelihood of this possibility is bolstered by the comparison of PA levels in past 
studies using a similar sample.  For example, Zautra et al. (2005) reported an average PA 
level of 2.78 (SD=.58) for the FM patients in that study.  In comparison, the FM patients 
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homozygous for asn40 in the current study reported a mean PA level across diary days of 
2.26 (SD=.74).  Thus, the average PA level experienced by homozygous asn40 carriers 
was quite low, even by FM standards.  This suggests that there may have been little room 
for those individuals to decline in PA on days of elevated pain.  Either way, the findings 
suggest that the 40asp allele is a source of resilience for FM patients.  Even on high pain 
days, they are able to maintain substantially higher PA levels than those of their 
genotypic counterparts.   
Diagnostic and genotypic differences emerged in the variance of pain reports.  
Both FM and OA/FM patients were more variable across diary days in their soft tissue 
pain than were OA patients.  This finding falls in line with the common understanding of 
widespread pain in FM: It is often closely related to environmental context, such as the 
presence of external social stressors, and is subject to wide and unpredictable fluctuations 
from day to day.  These variance scores, then, may reflect a pain process that could be 
described as reactionary.  Within the FM group, met/met individuals evidenced 
significantly greater variance in their pain scores than those with the val/val genotype.  
How does this between-genotype difference relate to the finding that met/met individuals 
experienced less PA on days in which pain was elevated?  It is possible that the greater 
variability in pain experiences for the met/met group led them to react more strongly in 
their positive affective response to pain elevations.  The met/met group did not 
significantly differ from other COMT groups in PA variance, suggesting that their more 
highly variable pain scores could have influenced their relatively stable PA variance.  
Perhaps the parallel between the diagnostic and genotypic differences in pain variance 
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suggests that met/met individuals, within the FM group, could be more prone to 
externally-influenced pain than those with a val158 allele.  
The current study also yielded some unexpected results with regard to tender 
point endorsement among participants from each diagnostic group.  Contrary to 
diagnostic criteria, about 17% of FM and OA/FM patients endorsed pain in fewer than 
the minimum 11 tender points needed to meet conditions for diagnosis.  In turn, nearly 
31% of OA-only patients endorsed pain in 11 or more tender points, suggesting that an 
FM diagnosis might be considered for this group.  Still, despite controlling for the 
discrepant tender point endorsements in the FM-only population, the primary gene and 
gene X environment findings remained.  This result supports recent assertions (Finan et 
al., In Press) that the diagnosis of FM may require a broader assessment than that put 
forth by the American College of Rheumatology (Wolfe et al., 1991).  That the effects of 
COMT and OPRM1 were observed with FM patients with and without the requisite 
number of tender points suggests that factors other than widespread pain serve to group 
these individuals.  Although the current study was specifically designed to examine FM-
only participants, further information could be gained from conducting similar gene and 
gene X environment analyses with the OA and OA/FM participants who met American 
College of Rheumatology tender point criteria.  Such an investigation would help 
determine the extent to which genes differentially affect behavior in primary FM, in 
which FM is the only diagnosed rheumatic disorder, versus secondary FM, in which FM 
is concomitant with another rheumatic disorder. 
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The findings presented in the current study have several implications for the 
diagnosis and treatment of FM.  The discovery of genetic association with behavior opens 
up the possibility of genetic screening to aid in treatment planning.  FM patients are 
notoriously difficult to treat, with treatment options ranging from opiate medication, 
antidepressant medication, psychotherapy, and a variety of alternative therapies including 
acupuncture and exercise (Arnold, 2006).  With genetic screening, practitioners would be 
able to tailor therapeutic regimens to FM patients most likely to succeed with a particular 
course of therapy.  For example, FM patients with the met/met genotype could be 
considered “at-risk” for ineffective positive affective regulation and treatment planning 
could pay particular attention to the scheduling of positive events.  For the minority of 
FM patients who carry the 40asp allele, positive affective regulation may be resilient to 
the chronic insult of widespread pain, so practitioners could focus treatment resources on 
other aspects of the syndrome that may be in greater need of support than positive 
affective regulation.  In any case, more research must be conducted before such treatment 
options are warranted.  The current findings must first be replicated in a different sample 
with more subjects.  If the findings can be replicated, clinical trials would be warranted to 
determine if FM patients of certain genotypes respond more favorably to one treatment 
approach versus another.  A study is currently underway in which FM patients will 
undergo a multi-week course of several psychotherapeutic and psychoeducational 
treatments, of which one is a mindfulness-based intervention that targets positive 
affective regulation, one is a cognitive-behavioral intervention that targets pain, and 
another is an education-only control.  Just such a randomized controlled trial would be an 
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ideal venue for testing the efficacy of genotypic grouping in the prediction of treatment 
outcomes. 
One issue raised by the present investigation is the question of whether there is a 
trajectory for recovery from FM and, if so, what, if any, role genetic factors may play in 
recovery.  The literature is sparse with empirical information pertaining to recovery from 
FM, and this may stem from the widespread controversy in the medical field over 
whether FM is really a disease.  The thinking holds: If there is no objective pathology to 
identify the disorder as a disease at baseline, then how can one ‘recover’ from something 
that does not exist (For a counter-argument, see: Mengshoel & Heggen, 2004)?  Still, 
longitudinal studies of the FM symptom trajectory have estimated FM recovery, as 
defined by failure to meet tender point criteria set forth by the American College of 
Rheumatology, to occur in 28-47% of the population at follow-ups ranging from 2-5.5 
years from baseline (Forseth, Forre, & Gran, 1999; Granges, Zilko, & Littlejohn, 1994).  
But, recovery from FM symptoms is likely more complex than the endorsement of fewer 
tender points, as evidenced by the variation in tender point endorsement in currently 
diagnosed patients from the present investigation.  Indeed, most patients in the Forseth et 
al. study still reported widespread pain at follow-up, suggesting that the impact of FM 
was still present despite the presence of fewer tender points.  What insight can behavioral 
genetics add to this debate?  The finding that carriers of the asp allele on OPRM1 are 
resilient in their positive affective regulation in the face of adversity raises the question of 
whether these individuals may have a greater potential for ‘recovery’ from FM, should 
such an outcome be possible.  It would be important to determine if these individuals 
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look similar in their positive affective regulation to patients from other chronic pain 
groups.  Hypothetically, if that were to be the case, treatment for these individuals could 
focus less on addressing affective issues and more on pain management.  Researchers 
could focus on the measurement of multiple trajectories for recovery, which could 
include, for example, a trajectory for pain symptoms, one for affective symptoms, and 
one for the affective reactivity to pain.  Behavioral genetic information, like that provided 
by the OPRM1 analyses in the present investigation, could aid in the interpretation of 
trajectories of recovery. 
The current findings, if replicated, could aid in the development of 
pharmaceuticals targeted to address both the pain and affective problems that characterize 
FM.  For instance, there is some suggestion that OPRM1 may be implicated in the 
pharmacological mechanisms of the antidepressant citalopram (Garriock & Hamilton, 
2008).  With regard to the typical narcotic treatment regimen for managing FM pain, 
physicians may be interested in knowing which OPRM1 variant is present in a patient 
before prescribing dosage.  40asp individuals may need a lower opiate dosage to produce 
sufficient reductions in pain and increases in positive affect, given their already high 
binding affinity for β-endorphin, as well as the evidence presented in the current 
manuscript suggesting resilient affective regulation in this group.  Further, a recent study 
found that cancer patients with the 40asp allele needed a 93% lower morphine dose to 
achieve pain relief than asn40 patients (Reyes-Gibby, Shete, Rakvag, et al., 2007).  
Interestingly, that study additionally found that cancer patients homozygous for the 158met 
allele on COMT needed 63% less morphine to achieve pain relief than those homozygous 
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for val158.  Although the 158met allele has typically been associated with greater pain 
sensitivity, it has also been associated with greater mu-opioid receptor binding potential 
(Zubieta et al., 2003), which may explain its association with increased morphine 
efficacy.  The findings in the present study support past evidence for pharmacological 
covariation of COMT and µ-opioid system functioning, and should encourage 
pharmacological researchers to take a multi-system approach in advancing the science on 
pharmaceutical treatment options for FM patients.  For this patient group, an ideal 
pharmaceutical agent would both reduce pain and help stabilize positive affect.  A 
systematic trial of opiate efficacy for FM patients should explore both pain relief and 
affective change as outcomes that may vary between COMT and OPRM1 genotypes.   
The current study proposed that OPRM1 would be a genetic source of resilience 
for FM women in that it would be associated with higher PA levels throughout pain 
elevations.  The evidence supported that hypothesis, but it is necessary to qualify the 
language used in my conceptualization of resilience.  Here, resilience was the 
maintenance of PA levels throughout 30 days of reporting that approximated those of OA 
patients reported in this and other samples (Zautra et al., 2005), with only minor dips in 
PA on days in which pain was elevated.  This form of resilience is similar to that 
described by Bonnano (2004), in which bereaved widows were termed resilient if they 
were able to live through the months following the loss of their spouse without 
experiencing depression symptoms.  We now know that FM patients characteristically 
have great difficulty gleaning the positive from daily experiences, especially those that 
are social in nature.  So, our minority group of FM patients with the 40asp allele displayed 
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a pattern of positive affective regulation that looked more like that of OA patients in 
terms of their ability to experience reward over time.  This is not to say, of course, that 
OPRM1 genotype was a direct cause of their resilient responding.  Indeed, for reasons I 
will enumerate below, it is now almost universally understood that no single gene can 
contribute enough variance to a complex behavioral pattern, such as positive affective 
regulation, to justify labeling that gene as a causal agent.  However, from a theoretical 
viewpoint, the current findings support the notion that neurobiological processes, at least 
partly determined by the code imparted by a genetic variant, can influence not just the 
risk of developing an illness, but the potential for one to be resilient through adversity. 
Limitations 
 As alluded to above, one major limitation of the current study was the single gene 
approach inherent to its design.  There has been much fervor in the field over the last 
decade about the candidate gene approach, as it was perhaps the first major technological 
advance in behavioral genetic research from the more inferential family/twin design.  The 
benefit of the candidate gene approach is that it leads research closer to the specific 
source of biological diversity that accounts for physical and behavioral abnormalities that 
natural selection should be working against.  However, as quickly as excitement has 
grown over the increasingly inexpensive methods to collect and genotype DNA that led 
to the proliferation of empirical studies reporting genetic associations with behavior, so, 
too, has that enthusiasm been tempered by the glut of small effect sizes, non-replications, 
and null findings.  The single genetic variant approach, as used in the current study, 
provides a compelling entrée into the vast possibilities of behavioral genetic research, but 
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is limited in what it can actually tell us about the biological sources of risk and resilience 
to the positive affective disturbance in FM.  Other currently available approaches could 
certainly expand the knowledge gained from the current study.  For example, the 
haplotype approach, used in identifying COMT-moderated pain sensitivity by Diatchenko 
et al. (2005), allows for the grouping of multiple variants proximally located with respect 
to a target SNP to be blocked together and analyzed based on their cumulative 
contribution to a behavioral phenotype.  Diatchenko et al.’s work, for example, shows 
that it may not be the 158met allele, alone, that accounts for pain sensitivity, but rather the 
interaction of that allele with alleles from SNPs in high linkage disequilibrium with 
val158met.   
 Another major limitation of the current study was the lack of control over 
medication usage.  Participants were enrolled whether or not they were currently taking 
opiates to help manage their pain, and their daily dosage throughout the diary reporting 
period was not monitored by research staff.  Naturally, this presents a confound to the 
effects of both OPRM1 and COMT, which are intricately related to opioid system 
functionality.  This is a hazard inherent to the daily process design with many FM 
patients, as disrupting ongoing medical treatment for study purposes for such a lengthy 
period would present perhaps too great a participant burden.  Future efforts could attempt 
to recruit an FM sample that is not currently taking opiate medication and compare the 
results to a sample that is currently prescribed opiates.  Although it would be difficult to 
rule out opiate intrusion or non-adherence, respectively, with those samples in a daily 
diary study, methods do exist that would enable the researcher to test for the presence of 
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opiates throughout the course of the study.  Such an undertaking, although burdensome, 
would provide greater clarity about the potentially confounding influence of opiate 
medication on COMT and OPRM1 effects in the FM population. 
 The current study was also limited in the respect that the gene and gene X 
environment effects were only examined in the FM population.  An extension of the 
study should include an analysis of gene X diagnosis and gene X diagnosis X 
environment effects on positive affective regulation.  The absence of such information 
limits the generalizability of the current findings, especially in light of recent data that 
should serve to reinvigorate the debate on primary versus secondary concomitant FM 
(Finan et al., In Press).  Although such analyses were possible in the current study, I 
chose to omit them due to concerns about power.  Thus, the small sample size limited the 
ability to examine genetic effects on positive affective regulation between rheumatic 
diagnoses.   
 Finally, the current study included only female participants.  Although FM 
primarily affects women, gender differences are widely reported in candidate gene 
studies in general, and a male comparison group may have provided important 
information about genetic differences in dynamics of pain and affect.  Future studies 
should include a male cohort to determine if the findings presented here are moderated by 
gender.  
Summary and Conclusions 
 Evidence has been provided in support of the hypotheses that variants on COMT 
and OPRM1 would be associated with the dual processes of pain and affect in FM.  The 
   
 
68
 
findings are unique in several respects.  First, they make use of repeated measurements of 
pain and affect collected across 30 days of electronic diary entries.  This methodology 
allowed for the examination of genetic associations with a stable PA phenotype, observed 
over time, as well as positive affective reactivity to naturally occurring perturbations in 
pain.  Naturalistic data such as those presented in the current study are crucial to our 
understanding of FM because pain for this patient population is often closely related to 
life stress and interpersonal processes that are, at best, imperfectly simulated in the 
laboratory.  By identifying two separate, but complimentary, brain systems that have 
been shown to contribute to pain and affective processing, the current study sought to 
determine if candidate genes known to regulate those systems were associated with a dual 
processing model of pain-related positive affective regulation in FM.  To that end, 
hypotheses that the val158met polymorphism on COMT and the asn40asp polymorphism 
on OPRM1 would serve as markers for FM risk and resilience, respectively, were 
supported.  Given the complexity of the behavioral phenotype chosen for investigation, 
the conclusions presented do not attempt to suggest genetic determinism for the 
development of FM or any of the characteristics associated with it.  Instead, the findings 
offer researchers ample reason to further investigate the contribution of the 
catecholamine and opioid systems, and their associated genomic variants, to the still 
poorly understood experience of FM.  In so doing, the field of behavioral genetics may 
provide basic scientists, behavioral scientists, and practitioners alike the knowledge 
necessary to advance the current state of conceptualization and treatment for FM.  
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Figure 1. Hypothesized model for COMT-moderated risk for positive affect deficit in 
FM.  Lines represent hypothesized risk of a deficit in positive affect for FM carriers of 
the 158met allele relative to FM carriers of the val158 allele, as well as moderation of the 
association of elevated daily pain with diminished positive affect. 
 
Figure 2a. Hypothesized model for OPRM1 association with daily positive affect.  Line 
represents a hypothesized association of higher positive affect for FM carriers of the 
40
asp allele relative to FM carriers of the asn40 allele. 
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Figure 2b. Hypothesized model for OPRM1-moderated resilience to elevations in pain in 
FM.  Lines represent a hypothesized interaction effect for FM carriers of the 40asp allele 
relative to FM carriers of the asn40 allele on the association of elevated daily pain with 
diminished positive affect. 
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Figure 3. COMT X pain interaction.  Slopes reflect PA reactivity to high versus low pain 
days for FM patients with either val/val, val/met, or met/met genotypes.  X-axis 
parameters were generated by dichotomizing centered pain scores into the top and bottom 
third of responses across participants.  
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Figure 4. OPRM1 X pain interaction.  Slopes reflect PA reactivity to high and low pain 
days for FM patients who are either carriers or not carriers of the asp allele.  X-axis 
parameters were generated by dichotomizing centered pain scores into the top and bottom 
third of responses across participants. 
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Table 1 
   
Means and Standard Deviations on Demographic Variables by Diagnosis  
 Fibromyalgia 
N=46 
Osteoarthritis/Fibromyalgia 
N=82 
Osteoarthritis 
N=86 
Demographic 
Variables 
M/% SD M/% SD M/% SD 
Age 52.98a 7.82 56.93b 8.13 60.01c 8.26 
Ethnicity  
(% 
Caucasian) 
93% a  94% a  94% a  
Income  
($30-40,000) 
76% a  44% a  67% a  
Note.  Values in each row sharing the same superscript are not significantly different 
from each other.  Significant differences were observed at the p<.05 level.  Means (M), 
percentages, and standard deviations (SD) of demographic variables were obtained by 
running descriptives in SPSS.  Percentage representation by Caucasians per diagnostic 
group is reported.  Percent within each diagnostic group reporting income at or above the 
sample median of $30-40,000 is reported.   
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Table 2 
Means and Standard Errors on Independent Variables by Diagnosis  
 Fibromyalgia  
N=46 
Osteoarthritis/Fibromyalgia 
N=82 
Osteoarthritis  
N=86 
Daily 
Psychological 
Characteristics 
M SE M SE M SE 
Positive 
Affect 
2.41a .11 2.23a .08 2.73b .08 
Negative 
Affect 
1.38ab .04 1.45b .04 1.30ac .37 
Soft Tissue 
Pain 
1.00a .08 1.08a .05 .40b .05 
Soft Tissue 
Pain Variance 
.13a .17 .13a .11 .05b .07 
Interpersonal 
Stress 
1.53a .05 1.55a .04 1.37b .04 
       
Note.  Values in each row sharing the same superscript are not significantly different 
from each other.  Significant differences were observed at the p<.05 level.  Means (M) 
and standard errors (SE) for the daily measures were obtained from the LS Means 
statement in PROC MIXED (Littell, 1996).  Positive and negative affect descriptives 
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were obtained by averaging across participants’ once-daily ratings, across all completed 
diary days, on the Positive and Negative Affect Schedule (Watson, Clark, & Tellegen, 
1988).  Soft tissue pain descriptives were obtained by averaging participants’ once-daily 
ratings of pain, across all completed diary days, computed from 15 soft tissue “zones” on 
the body.   Interpersonal stress descriptives were obtained by averaging participants’ 
once-daily ratings of stressfulness across four domains of interpersonal interaction: 
spouse, family, friends, and work.  Participants were instructed to give all affect, pain, 
and stress ratings before going to bed at night. 
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Table 3 
Correlations Among Study Variables 
 Positive Affect Negative 
Affect 
Soft Tissue 
Pain 
Interpersonal 
Stress 
Positive Affect 1.00 -.27** -.20** -.19** 
Negative Affect - 1.00 .30** .56** 
Soft Tissue Pain - - 1.00 .33** 
Interpersonal 
Stress 
- - - 1.00 
Note. Variables included in the table above were averaged for each participant across 
diary days and then correlated. 
**p<.01 
 
 
 
 
 
 
 
 
 
 
   
 
77
 
Table 4 
Allelic Frequencies for COMT and OPRM1 by Diagnosis 
 Fibromyalgia  
N=46 
Osteoarthritis/Fibromyalgia 
N=82 
Osteoarthritis  
N=86 
Catechol-O-
Methyltransferase 
% Representation % Representation % Representation 
val/val 26.1 22.0 29.1 
val/met 52.2 56.1 58.1 
met/met 21.7 21.9 12.8 
µ-Opioid Receptor    
Asp 23.9 28.0 30.2 
asn/asn 76.1 72.0 69.8 
Note. Values in each row are the percentage representation of each measured genotype, 
separated in columns by participant diagnosis.  No significant differences between 
diagnoses in allelic representation were found. 
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Table 5 
Means and Standard Deviations of Positive Affect by Genotype and Diagnosis 
 Fibromyalgia  
N=46 
Osteoarthritis/Fibromyalgia 
N=82 
Osteoarthritis  
N=86 
Catechol-O-
Methyltransferase 
M SD M SD M SD 
 val/val 2.43a .73 1.98a .58 2.89a .98 
val/met 2.37a .83 2.23ab .67 2.71a .84 
met/met 2.37a .98 2.44bc .84 2.69a .56 
µ-Opioid 
Receptor 
      
 Asp 2.78a .80 2.23a .64 2.87a .98 
asn/asn 2.26b .74 2.20a .64 2.71a .80 
Note. Means and standard deviations are provided for PA, aggregated across diary days.  
Columns reflect values for each diagnosis, with each row representing a measured 
genotype.  Comparisons were made between genotype, within each diagnosis.  Values in 
each mean column (separately, for each diagnosis) that do not share a common 
superscript are significantly different from each other, p<.05.  
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Table 6 
COMT Moderation of Daily Pain Effect on Daily Positive Affect 
Random Effects 
Covariance Parameter 
Estimates 
Subject β SE Z p 
Intercept ID .06 .13 4.40 <.001 
Residual ID .32 .02 20.23 <.001 
 Fixed Effects 
Predictor Variables β SE df t p 
Level 1 
∆ in Daily Pain (∆Pain) -.57 .09 1217 -6.07 <.001 
Level 2 
COMT (val/val vs. met/met) .08 .35 42 .24 .81 
COMT (val/met vs. met/met) -.001 .31 42 -.01 .99 
Covariate 
Negative Affect -.29 .04 1217 -7.56 <.001 
Level 1 X Level 2 
∆Pain X COMT  
(val/val vs. met/met) 
.37 .16 1217 2.34 <.05 
∆Pain X COMT  
(val/met vs. met/met) 
.31 .11 1217 2.78 <.01 
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Note. The results of the multilevel analysis of the cross-level interaction of COMT 
genotype and within-person centered daily pain (∆Pain) on daily positive affect among 
fibromyalgia patients are presented.  The effects presented for each Level 2 and cross-
level effect are separated according to contrast with the target group, met/met individuals. 
met/met= individuals homozygous for the met allele; val/met = individuals with a 
heterozygous genotype; val/val = individuals homozygous for the val allele. 
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Table 7 
OPRM1 Moderation of Daily Pain Effect on Daily Positive Affect 
Random Effects 
Covariance Parameter 
Estimates 
Subject β SE Z p 
Intercept ID .53 .12 4.43 <.001 
Residual ID .32 .02 20.27 <.001 
 Fixed Effects 
Predictor Variables β SE df t p 
Level 1 
∆ in Daily Pain (∆Pain) -.28 .05 1218 -5.18 <.001 
Level 2 
OPRM1 (asp vs. asn/asn) .50 .26 43 1.93 .06 
Covariate 
Negative Affect -.29 .04 1218 -7.39 <.001 
Level 1 X Level 2 
∆Pain X OPRM1  
(asp vs. asn/asn) 
-.32 .13 1218 -2.46 <.05 
Note. The results of the multilevel analysis of the cross-level interaction of OPRM1 
genotype and within-person centered daily pain (∆Pain) on daily positive affect among 
fibromyalgia patients are presented.   
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asp= individuals either homozygous for the asp allele or heterozygous for the asp and asn 
alleles;   asn/asn = individuals homozygous for the asp allele
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These words describe different feelings and different emotions. 
How much have you felt this way today? 
1 = very slightly/not at all    2 = a little    3 = moderately    4 = quite a bit    5 = extremely 
Positive Affect Negative Affect 
Interested Distressed 
Alert Upset 
Attentive Guilty 
Excited Ashamed 
Enthusiastic Hostile 
Inspired Irritable 
Proud Nervous 
Determined Jittery 
Strong Scared 
Active Afraid 
 
 
 
 
 
 
 
  
APPENDIX B 
SOFT TISSUE PAIN SILHOUETTE 
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